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Abstract:  
Chlamydia trachomatis is the most frequently reported bacterial sexually transmitted 
infection worldwide. Even after a C. trachomatis infection is treated, there is an increased 
risk for the development of pelvic inflammatory disease and cervical cancer, but the 
underlying mechanisms are poorly understood. C. trachomatis usurps many host cell-
signaling pathways from within a membrane bound vacuole, called an inclusion. C. 
trachomatis is also known to synthesize and secrete via the type III secretion system, 
inclusion membrane proteins (Incs) that are inserted into the inclusion membrane and 
serve as the interface between Chlamydia and the host. C. trachomatis is the first 
bacterial pathogen observed to recruit myosin phosphatase (MYPT1) for means of host 
cell exit, by extrusion, and does so through the chlamydial Inc protein, CT228. In this 
study the chlamydial TargeTronTM system was used to genetically inactivate CT228 in 
the C. trachomatis genome and genetically perform complementation of CT228 in trans 
to successfully restore MYPT1 recruitment in the mutant. Currently, in vivo models of 
infection continue to be instrumental in elucidating the pathogenesis of and immune 
response to this intracellular bacterium, however significant gaps in our understanding 
exist when utilizing such. The second objective of this study was to produce a side-by-
side comparative analysis in a cervicovaginal murine infection model utilizing the C. 
trachomatis serovars D and L2 and the C. muridarum strain, MoPn, by characterizing the 
time course of infection and Chlamydia shed and obtaining gross pathology following 
clearance of active infection. A key finding herein is the first identification of chlamydial 
extrusions shed from host cells in an in vivo model.  Extrusions, a phenotype made 
possible through a dynamic involving CT228 and MYPT1, had been previously observed 
solely in vitro. The results of this study demonstrate that chlamydial extrusions exist in 
vivo, representing a possible host dissemination method, thus warranting further 
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Chlamydiae are unique obligate intracellular organisms capable of being human 
pathogens. Clinically, among human infections, C. trachomatis and C. pneumoniae are of 
concern.  C. trachomatis is separated by clinical manifestation and serovars.  Serovars A-
C are known to cause infectious blindness in developing countries, most commonly 
referred to as trachoma, serovars D-K are urogenital in nature and serovars L1, L2 and L3 
are known to produce lymphogranuloma venereum (LGV) infections (Baehr et al., 1988; 
Burton & Mabey, 2009). Most recently, a reclassified member of C. trachomatis is C. 
muridarum, a strain known to cause infections in mice, called mouse pneumonitis 
(MoPn) (Everett et al., 1999).  
Chlamydiae require a host cell, for replication, due to their characteristic of being 
an obligate intracellular pathogen.  Chlamydiae are unique in that they are biphasic in life 
cycle; alternating between two forms, Elementary Bodies (EBs) and Reticulate Bodies 
(RBs). EBs are 300 nm in diameter, metabolically inactive, infectious and extracellular, 
having the capability to attach to host cells; whereas, RBs are 1000 nm in diameter, 
intracellularly replicating and modify the inclusion membrane. The chlamydial cell 
membrane is quite typical of other Gram-negative bacteria, containing a recently 
identified peptidoglycan layer (Liechti, et al. 2014). After initial attachment to host cells,  
2	  
	  
Chlamydiae gain entry into the host cell through endocytosis, avoid lysosomal fusion and 
degradation, form a parasitophorous vacuole, termed an inclusion, and usurp many host 
cell processes by the recruitment of host proteins. 
After forming an inclusion, EBs rapidly differentiate into RBs and after filling the 
host cell to capacity, the growing numbers of Chlamydiae must then exit by one of two 
mechanisms: lysis, or extrusion. The lytic host cell escape mechanism occurs in a distinct 
sequence of events: inclusions membrane permeabilization followed by nucleus 
permeabilization and ultimately, plasma membrane permeabilization (Hybiske & 
Stephens, 2007).  Recently, Yang et al. demonstrated that lytic escape is dictated by the 
chlamydial plasmid. This single chlamydial plasmid carries eight genes, of which, Pgp4 
is a known transcriptional regulator of several chromosomal genes—each required for 
lytic host cell exit.  Furthermore, Yang et al. also show that the type 3 secretion system is 
required for Pgp4-regulated lytic escape.  While the complete mechanism is not yet 
known, the description of chlamydial lytic escape provides further support of the ability 
of Chlamydiae to manipulate the host cytoskeleton during active infections (Yang et al., 
2015).  
Alternatively, the chlamydial host cell exit mechanism of extrusion involves a 
highly dynamic pathway including a series of interactions between host cell proteins and 
Chlamydia-synthesized proteins.  The host cell protein MYPT1, a subunit a myosin 
phosphatase, and the chlamydial inclusion membrane protein, CT228 are known to 
interact during infection (Lutter et al., 2013).  It is known that MYPT1 is recruited to the 
periphery of the chlamydial inclusion in rich active enzymatic patches, deemed 
microdomains (Mital et al., 2010).  The extrusion mechanism in total is dependent on the 
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substrate of host protein MYPT1: myosin light chain 2 (MLC2).  MYPT1 enzymatically 
removes phosphate groups from MLC2, dictating overall activity. Phosphorylated MLC2 
is in an activated state, as when MYPT1 is interacting with CT228 at the inclusion unable 
to dephosphorylated the substrate, and MLC2 is able to interact with binding partners 
myosin IIA and myosin IIB, associating with MLC2 to form an active myosin motor 
complex. This leads to the overall host cell exit mechanism preference towards extrusion 
rather than lysis. However, if MYPT1 does not interact with CT228 during infection, 
lytic events are preferred as MYPT1 does not phosphorylate the substrate MLC2 (Lutter 
et al., 2013).   
The first account of the novel adaptation of the commercially available 
TargeTron™ system in Chlamydiae was published in 2013, when Johnson & Fisher 
successfully genetically inactivated the chlamydial protein, IncA (Johnson & Fisher, 
2013). To continue investigating of the interactions of CT228 and MYPT1, a novel 
adaptation of the commercially available TargeTronTM system, the second to date in 
Chlamydiae, is described here. Furthermore, the novelty in this investigation if only 
heightened by the first account of successful complementation in trans of CT228 in the 
TargeTronTM system.  
Additionally, a full comparison of chlamydial strains in vivo was utilized to 
establish a chlamydial murine model for future investigations. The murine model has 
been used to study chlamydial infections, as there is a close resemblance of genital 
infections in the mouse resembling human female genital infections (Williams et al., 
1981).  Following murine genital infection, mice typically resolve infections naturally 
and develop a subsequent immunity approximately 4 weeks after infection. After the 
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clearing of infection, more than half of mice are typically resistant to reinfection 
(Morrison & Caldwell, 2002). It was found that MoPn is more virulent than C. 
trachomatis in the murine genital infection model, causing systemic infections and acute 
pathology in the genital tract (Nigg, 1942). Within several days following initial 
infection, neutrophils and monocytes respond at the site of infection (Morrison & 
Morrison, 2000). Following this neutrophil recruitment, T cells accumulate at the 
infection site and maintain a critical role during and after infection clearance (Kelly & 
Rank, 1997; Darville et al., 1997; Ramsey & Rank, 1991; Morrison et al., 1995). CD4+ T 
cells predominate during the infection time course, in comparison to CD8+ T cells, and in 
the genital tract mucosa can be observed in small clusters until the resolution of infection 
(Morrison et al., 1995). 
To date, many studies have encompassed topics such as chlamydial infectivity, 
pathogenicity, infertility and potential vaccine candidates for MoPn and C. trachomatis 
infections in the murine model (Hong et al., 2012, Pal et al., 1999; Schautteet et al., 
2011). However, troubles arise in respect to the availability of a wide variety of murine 
models to choose from.  Furthermore, difficulties also lie in the lack of consistency in 
model utilization. Hence, there lies a broad gap in knowledge, which does not permit for 
any clean comparisons across the board. A platform can be established for the basis of 
many investigations to come by characterizing and comparing serovars of C. trachomatis 
serovar D, serovar L2 and C. muridarum MoPn in vivo, within the same murine infection 
model. Uniquely, this study is the first to utilize the ocular chlamydial serovar D, the 
urogenital serovar L2 of C. trachomatis and the murine serovar MoPn of C. muridarum 
in vivo.  Furthermore, a full comparison of immune response and recoverable infectious 
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forming progeny is obtained.  This study allows for insight into the time course of 
chlamydial infections and gross pathology following clearance of infection.  
Unexpectedly, and demonstrated for the first time, is the account of chlamydial 
extrusions in the in vivo murine infection model.  
The aim of this thesis was to investigate two distinct, yet related objectives 
regarding chlamydial pathogenesis: 
• Characterize and complement, in trans, the chlamydial CT228 
mutant created by the adapted TargeTron™ system.  
• Perform in vivo comparison of C. trachomatis serovar L2, C. 
trachomatis serovar D/LC and C. muridarum MoPn within the 
same murine model to establish the timeline of infection and 






REVIEW OF LITERATURE 
 
II. A. Taxonomy 
Chlamydiae are capable of infecting a wide array of eukaryotic hosts including 
humans, ruminants, toads, and birds but typically are observed to replicate within 
epithelial cells.  Based on 16S and 23S rRNA sequences, a phylogenetic analysis of 
Chlamydiae was put forth by Everett et al. in which taxonomy of chlamydial species is 
done through criteria of genetic, morphological and phenotypic means. The only order of 
Chlamydiales, consisting of families: Chlamydiaceae, ParaChlamydiaecae, 
Simkaniaceae and Waddliaecae (Everett, Bust et al., 1999).  However, in 2009, Stephens, 
Myers, et al., proposed to reunite the family Chlamydiacae into a single genus: 
Chlamydia (Stephens, Meyers et al., 2009).  
II. B. Clinical relevance 
 Chlamydiaceae are the infectious agents of many human and animal diseases. In 
humans, two species are of greatest concern: C. pneumoniae and C. trachomatis.  C. 
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 pneumoniae is known to be associated with the formation of pulmonary illness and 
chronic infections which are associated with an enhanced risk of the development of 
atherosclerotic, cerebrovascular, and chronic lung disease (Saikku et al.,1988; Martin et 
al., 1996; Saikku et al., 1992). C. trachomatis causes both urogenital and ocular 
infections. While serovar type is typically separated by which area of the body suffers 
infection, it has been shown that serovars can infect alternative areas than expected.  
Typically, urogenital infections are caused by serovars D-K and lymphogranuloma 
venerum serovars L1-3, whereas ocular based infections serovars also exist. Serovars A-
C are the leading cause of infectious blindness worldwide, observed to be mainly located 
in developing countries (Burton & Mabey, 2009). Human hosts obtain the infection 
through contact with other infected eye secretions and also contact with flies. Through 
repetitive blinking, due to the eyelids folding inwards due to the infection, the cornea is 
scratched beyond repair and blindness often results (Burton & Mabey, 2009).  
Chlamydial infections are the most commonly reported sexually transmitted 
infection (STI) worldwide with an estimated 131 million incidences each year (Newman, 
et al., 2015). In female hosts, sexually transmitted C. trachomatis infections are the major 
cause of cervicitis, infertility and PID to name a few in female hosts and urethritis and 
epididymitis in male counterparts (Brunham et al., 1984) (Paavonen & Eggert-Kruse, 
1999). In many cases, chlamydial STIs can be present in a silent manner. In fact, 
asymptomatic female patients are very typical of chlamydial sexually transmitted 
infections when compared to male counterparts. Nearly 75% of females and 50% of 
males are asymptomatic in C. trachomatis infections (Stamm, 1999; Gonzales et al., 
2004). Even after clearing of an infection with antibiotics, such as azithromycin 
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(Zithromax; 1 g single dose) or doxycycline (100 mg twice daily for seven days), women 
especially are at high risk for developing pelvic inflammatory disease (PID), infertility, 
perihepatitis, ectopic pregnancy and tubal scarring and even Chlamydia-induced reactive 
arthritis are also possible (Mishori et al., 2012). It has been suggested that prolonged 
antimicrobial therapy of up to six months consisting of combinational antibiotics could be 
effective at treating Chlamydia-induced arthritis (Carter et al., 2010). While there are 
numerous complications after a chlamydial infection, to date the most definitive method 
of prevention of infection is by practicing abstinence. Also shown to be effective in 
prevention of infection is a lifestyle of being in a long-term, mutually monogamous 
relationship (Workowski & Berman, 2011).  
C. muridarum, as recently stated, was once defined as a serovar of C. trachomatis. 
However, after phylogenetic 16S analysis and sequencing, it was determined that C. 
muridarum was a separate species. There are currently two isolates of C. muridarum: 
Weiss isolate and Nigg isolate. Differences in the two strains are due to inclusion size, 
plaque size and single nucleotide polymorphisms (Ramsey et al., 2009). C. muridarum is 
known to cause respiratory infection and pneumonia in mice, mouse pneumonitis 
(MoPn). Also, MoPn can be used to successfully infect the urogenital tract in mice, 
serving as the first model for human chlamydial infections (Barron et al., 1981).  
II. C. Chlamydial Growth and Development 
II. C. i. Entry 
The chlamydial entry mechanism has been a bit of a mystery in the past. 
Previously, it was thought that one of two plausible hypotheses could explain the 
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mechanism chlamydial host cell entry. The first mechanism of entry involves a 
sequential, zipper-like microfilament-dependent process of phagocytosis, which requires 
contact between bacterial adhesins and host cell receptors (Finlay & Cossart, 1997; Wart 
& Murray, 1984). The second involves uptake into clathrin -coated vesicles by receptor 
mediated endocytosis (Hodinka et al., 1988). EBs are much larger in size than the normal 
clathrin-coated vesicles and despite this, they appear capable of exploiting this 
mechanism of host cell entry. Though strain specific, Chlamydiae are capable of entering 
the host by either route, static or centrifuge-assisted (Prain & Pearce, 1989). However, 
much has been learned in present times about chlamydial entry. 
 Currently, the accepted hypothesis of chlamydial host cell entry involves the 
translocation of an actin-recruiting protein (Tarp) into the host cell (Clifton, et al. 2004). 
The proposed mechanism is as such: the Tarp protein, also known as chlamydial ORF 
CT456, is present in EBs in an unphosphorylated state prior to the point of host cell entry. 
It is suggested that following the attachment of the EB to the host cell, Tarp (CT456) is 
phosphorylated at its position at the cytoplasmic face of the host plasma membrane where 
it is then phosphorylated at a tyrosine residue (Fawaz et al., 1997). Following 
phosphorylation, Tarp, which is a presumed type III secreted effector protein, is observed 
to recruit actin to the site of initial EB attachment, in which aggregation of actin is 
observed (Birkelund et al., 1997, Cliffton et al., 2004). The recruitment of actin following 
chlamydial host cell entry has been well studied in the past. It was found that several 
proteins, Arp2/3 complex, WAVE2 and various other actin-associated proteins such as 
Cdc42 and Arf6, colocalize with entering EBs in an ordered and rapid fashion (Carabeo 
et al, 2004). Also found to be colocalizing at the site of entry was Rac, a GTPase Rho 
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family member (Carabeo et al., 2002; Carabeo et al, 2004).  
After endocytosis, EBs avoid the endocytic pathway and traffic away from 
lysosomes and rapidly transform into RBs that continue to replicate within the inclusion. 
Endocytosis is obtained by pinocytosis in clathrin-coated pits or by phagocytosis 
(Reynolds & Pearce, 1990). Upon entering into eukaryotic cells, F-actin is redistributed 
and the polymerized actin participates in the redistribution of the microorganisms 
(Reynolds & Pearce, 1991; Carabeo et al.,2002). Upon C. trachomatis attachment to 
HeLa 229 cells, tyrosine phosphorylation of host cell proteins at the attachment site is 
induced which consequently is associated with F-actin, aggregation, and Ca2+ 
dependencies, and determines the next set of events in chlamydial infection, in which 
microfilament network importance is highlighted (Birkelund et al., 1994).  
The microfilament networks, as well as dynein and kinesin motor proteins, have 
distinct roles of internalization and development. Determined through phagocytosis 
inhibition by the addition of Cytochalasin D and by motor protein blockage, it was 
observed that unlike C. trachomatis, C. psittaci can use both microfilament dependent 
and independent entry pathways. Whereas, internalization and development mainly relied 
on microfilaments or microtubules, specifically, actin and tubulin networks which were 
also necessary for growth optimization (Escalante-Ochoa et al., 2000).   
II. C. ii. Biphasic Life Cycle 
Chlamydiae alternate between two morphological forms, the elementary body 
(EB) and the reticulate body (RB) (Moulder, 1991). Initially, extracellular EBs attach to 
susceptible eukaryotic host cells at which point the EBs are internalized and create a 
membrane bound, parasitophorous vacuole, termed an inclusion.  EBs differentiate into 
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metabolically active forms, RBs, and undergo multiple repeated cycles of binary fission, 
which leads then into the secondary differentiation back into the metabolically, infectious 
form of EBs.  The host cell fills to capacity due to the growing numbers of Chlamydia, at 
which point they must exit the host cell.  Either by lysis, releasing thousands of EBs to 
infect adjacent neighboring cells, or alternatively by extrusion, a packaged release 
mechanism in which the inclusion slowly protrudes and detaches from the host cell 
(Hybiske & Stephens, 2007). Upon treatment with antibiotics, a targeted stressful 
environment is created in which the developmental cycle is disrupted, causing large 
aberrant RBs (Hogan et al., 2004). This observation was ultimately attributed to the 
continued expression of genes controlling DNA replication but was not independent of  
genes contributing to bacterial cellular division.  
II. C. iii. The Elementary Body 
EBs are the small (0.3 um), round, electron dense, infectious form of Chlamydia 
(Eb et al., 1976). The EB is highly compacted in nuclear material due to the presence of 
bacterial histone-like proteins HctA and HctB (Brickman et al., 1993; Barry et al., 1992). 
The nucleoid location within the cell body suggests for an association with the cell wall 
or bacterial-inner membrane.  EBs were once thought to be unusual in that little to no 
peptidoglycan is present in the cell membrane, despite Chlamydia encoding for 
peptidoglycan synthesizing genes and also, despite the fact that Chlamydia exhibits 
sensitivity to peptidoglycan targeting antibiotics. However, it was found by a unique cell 
wall labeling technique involving the use of D- amino acid probes, that in fact, 
Chlamydia does in fact possess a functional peptidoglycan structure (Liechti, et al. 2014). 
Further structural rigidity is due to highly cross-linked disulfide bond presence amongst 
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outer membrane proteins rich in cysteine residues. For example: Outer Membrane Protein 
A (OmpA), Outer Membrane Complex protein B (OmcB), and Outer Membrane Protein 
Complex A (OmcA) (Hatch, 1999, Liu et al., 2010, Hou et al. 2013). Additionally, 
hexagonally dispersed protein layer consisting mainly of OmcB at the inner surface of the 
outer-membrane complex is hypothesized to contribute to cellular stability of the EB.   
With the usage of electron microscopy, the EB is presented as a hexagonally 
organized surface with projections arranged regularly with a center spacing of 
approximately 50nm (Nichols et al., 1985; Matsumoto, 1982). These supramolecular 
structures extend 30nm from the EB surface and have rotational symmetry similar to a 9-
subunit composition.  It has been speculated that these spike-like projections are actually 
the needle structure of the T3SS. It is now known that all species of the Genus Chlamydia 
within the order Chlamydiales contain genomes, which encode for the non-flagellar type 
III secretion system (NF-T3SS), providing further evidence for this speculation (Büttner, 
2012).  
II. C. iv. The Reticulate Body 
     The process of transitioning from a metabolically inactive, infectious form of EB 
to the metabolically active, non-infectious form of RB can be prevented by addition of 
antibiotic inhibition preventing transcriptional and translational cellular processes.  This 
suggests that protein expression is required for the beginnings of intracellular growth 
(Scidmore et al., 1996). The reticulate body (RB), arises quite quickly from the 
elementary body (EB), following the primary differentiation.  RBs are much larger than 
the 0.3um EB, measuring at approximately 1um.  The cytosol of the RB is filled with 
nucleic acid, which, in comparison to the EB which is highly condensed and filled with 
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nucleic acid.  RBs are non-infectious, metabolically active, and contain ban inner and 
outer membrane.  The RB is covered with projections, which extend from the bacterial 
surface. Gene expression continues throughout RB development and at mid-development 
cycle during which, RBs undergo binary fission, exponentially replicate in numbers, 
eventually going through a secondary differentiation period followed by ultimate host 
cell egress mechanisms (Rocket & Matsumoto, 2000).   
 
II. D. The Type III Secretion System 
Previously, the hypothesized T3SS of Chlamydiae was further supported by 
findings that projections visualized with SEM, were indeed that of the T3SS needle. 
Based on past models of research in heterologous system in Yersinia, inclusion 
membrane proteins were found to be T3SS substrates (Büttner, 2012). This suggested that 
EBs must have pre-formed T3SSs, which function rapidly upon the EB-host cell 
interaction.  Further supporting the presence and functioning of the T3SS in the initial 
stages of host cell attachment and interaction (Clifton et al., 2004).  
All species of the Genus Chlamydia within the order Chlamydiales contain 
genomes which encode for the non-flagellar type III secretion system (NF-T3SS).  More 
than 20 proteins associate to form an apparatus, the injectisome, to accomplish vector 
secretion and translocation of anti-host effector proteins.  Chlamydia is unique in that the 
NF-T3SS genes are not located on virulence plasmids nor are they arranged into 
pathogenicity islands.  Rather, effector genes are dispersed throughout the chromosome 
in all chlamydial species. However, apparatus components are grouped into three distinct 
and major loci.  There is no evidence within the genome of transposons, insertion 
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sequence elements, or horizontal gene transfers that would suggest recent acquisitions of 
the T3SS capabilities (Stephens et al., 1998). However, Chlamydia is consistent with a 
model described by phylogenetic comparison: the T3SSs have lost the flagellar genes and 
thus losing motility. Furthermore, the model suggests that additional genes were 
subsequently acquired and included those required for outer membrane secretin and 
secreted translocon (Abby et al., 2012). The current evolutionary model suggesting such 
may serve reason; however, the apparent genetic grouping of NF genes (cdsD) along with 
other genes from the T3S core apparatus suggests that chlamydial T3SS arose after the 
evolution of a common precursor of the NF-T3SS.  However, it is possible that genes 
were obtained en bloc but spontaneously over time, which may serve as evidence of the 
current chlamydial genomic distribution (Jeffery et al., 2010).  
It is at the point of EB contact to a host cell in which the T3SS is activated and 
actively secreting injectisomes present on RBs. Such secretion through the injectisome is 
turned off as a result of RBs differentiating back into EBs later during infection.  These 
injectisome serve a key purpose: to mediate the secretion of early developmental cycle 
effectors.  It serves this key purpose to compensate for the fact that synthesis of T3SA 
genes do not occur until mid-development, correlating with the time in development 
where Chlamydiae start to divide for the first time (Belland et al., 2003). It is also shown 
that EBs are preloaded with vast amounts of chaperones and effectors; whereas, in late 
cycles of development, RBs possess little amounts of chaperones and apparatus 
components (Saka et al., 2011). It is suggested that the NF-T3SS is regulated partially by 
disulfide bonding from within the T3SA components themselves.  The EB envelope is 
highly covered in disulfide cross-linkages.  Such bonds are reduced as the chlamydial 
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EBs differentiate into RBs (Moulder, 1991). The NF-T3SS needle protein, CdsF, contains 
many cysteine residues, which is typical amongst secretion system needle proteins (Betts 
et al., 2008). Furthermore, disulfide bonding within such needle correlates with 
developmental stages (Betts-Hampikian & Fields, 2011). Hence, the disulfide bonding 
mechanism could confer structural rigidity and have a role in the control of secretion 
simultaneously. T3SS chaperones directly bind T3S substrates and facilitate secretion 
through the injectisome (Fattori et al., 2011). The T3SS chaperones are dimeric, cytosol-
localized proteins and function to protect their substrates from degrading, maintaining the 
partially unfolded state for competence, and prevents substrates from other protein 
interactions prematurely for the goal of ultimate direct targeting of the substrates to the 
T3SA components selected for interaction. T3S chaperones are classified and divided 
into categories based on substrate specificity.  Class IA bind single effector substrates 
while class IB binds multiple effector substrates.  Class II binds translocon components 
and class III binds needle subunit proteins (Parsot et al., 2003). Collectively, T3SS 
chaperones are proteins, which most likely play critical roles in T3SA assembly, 
translocon secretion and assembly, and establish the efficient translocation of effector 
proteins into the host.  
II. D. i. Secreted Effector Proteins 
During chlamydial infection, protein effectors orchestrate many functions by 
direct association, enzymatic modification, or mimicry of target host factors to facilitate 
molecular requirements of virulence in a system (Dean, 2011). Chlamydiae, being an 
obligate intracellular pathogen, possess a wide array of effector proteins. These effector 
proteins function to direct association, enzymatically modify, mimic target host factors 
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and facilitate molecular requirements of virulence (Dean, 2011). Detecting chlamydial 
effector proteins is problematic due to the lack of a predictable T3S substrate secretion 
signals.  Despite effectors from other pathogens containing a consensus domain, all 
efforts to predict chlamydial effectors in the same way have failed due to short sequence 
length, error rates in sequence based analyses for prediction verifications, and many false 
positives in the identification of candidate substrates. Two broad classes of effectors have 
emerged from recent ongoing studies, and are classified as either invasion-related or 
inclusion membrane (Inc) class effectors (Dean, 2011; Arnold et al., 2009; Samudrala et 
al., 2009; Subtil et al., 2005).  
II. D. ii. Invasion-related Effector Proteins 
Typical of invasion-related, or more commonly known as effector proteins, is the 
secretion of the protein into the host cell cytosol (Kleba & Stephens, 2008). Past 
difficulties in the identification of chlamydial host cell cytosolic effector proteins is due 
to the impossibility to separate the cytosolic compartment of Chlamydia-infected cells 
from the inclusion and inclusion membrane. This is due to the sensitivity observed of the 
inclusion after lysis to host cells (Heinzen & Hackstadt, 1997). However, Kleba and 
Stephens describe an important contribution to the Chlamydial field with the report of a 
protocol, in which recovery of a soluble cytosolic fraction from Chlamydia-infected cells 
is indeed possible (Kleba & Stephens, 2008). This work allowed for the identification of 
more than 20 chlamydial proteins observed to be localized to the cytosolic compartment 
by the use of cholesterol-dependent cytolysin perfringolysin O (PFO), which 
permeabilizes the plasma membrane of HeLa 229 cells to obtain a soluble cytosolic 
protein fraction. However, with this approach there are current limitations: proteins 
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present in small quantities are not amenable to identification by mass spectrometry, the 
identified proteins are not representative of the total population of bacterial proteins 
translocated beyond the inclusion membrane due to limitations of the design, and lastly, it 
is possible that chlamydial proteins are may be trapped within the cell after PFO 
treatment due to interaction with other proteins (Kleba & Stephens, 2008). Current efforts 
in the field are targeted to further identify and characterize chlamydial secreted host cell 
cytosolic effector proteins (Yang et al., 2015; Markham, et al. 2009).  
II. D. iii. Inc-class Effector Proteins 
Inc proteins are recognized as T3S substrates fundamental to biogenesis and 
inclusion modification and maintenance (Subtil et al., 2001; Dehoux et al., 2011). Inc-
class effectors are described as proteins localizing to the inclusion membrane, which 
contain predicted bilobed hydrophobic domains of more than 60 residues (Bannantine et 
al., 1998). Although a majority of inclusion membrane proteins are hypothesized to have 
important roles in pathogenesis, current difficulties lie in the prediction of function (Shaw 
et al., 2000).  
First, there is little sequence similarity amongst Incs. Secondly, bioinformatic 
analysis provides little clues as to function because of this low sequence similarity 
(Bannantine et al., 2000). Further creating difficulties in prediction and characterization 
of Incs is an observed poor conservation amongst chlamydial species.  For example, IncA 
was first identified in C. caviae (Rockey et al., 1995; Rockey & Rosquist, 1994).  Despite 
this identification, IncA has a function only described in C. trachomatis (Hackstadt et al, 
1995; Stephens et al., 1998; Hackstadt et al., 1999). However, despite difficulties 
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mentioned previously mentioned, several Incs have been described in function and 
characterized. Currently characterized Incs include: CT850, CT229, IncA, IncD, IncG, 
CrpA and CT228 (CT850, CT229, CT119, CT115, CT118, CT442 and CT228, 
respectively). CT850 was found to interact with dynein light chain (DYNLT1) which is 
known to assist in the correct positioning of the inclusion at the MTOC (Mital et al., 
2015). The regulation of intracellular trafficking or fusogenicity of the inclusion is in part 
due to the recruitment of Rab4 to the site of the inclusion membrane during infection by 
interaction with chlamydial protein, CT229 (Rzomp, et al. 2006).  IncA interacts with 
host endocytic SNAREs at the SNARE motif (Delevoye et al., 2008; Paumet et al., 
2009). CT119 IncD interacts with host cell protein, CERT, at an undetermined domain 
(Derré et al., 2011). Chlamydial protein CT118, IncG, interacts with 14-3-3-beta at the 
14-3-3 binding motif (Scidmore & Hackstadt, 2001). CrpA, CT442, elicits a CD8+ T cell 
response and also partially protects from subsequent infections with C. trachomatis 
(Starnback et al., 2003). Chlamydial protein CT228 was shown to interact with a 
component of myosin phosphatase, MYPT1. Such interaction controlled the dynamic of 
host cell exit, to preferably cause the bacteria to exit the cell by extrusion rather than by 
lysis (Lutter et al., 2013). Other inclusion membrane proteins have yet to be described. 
This is due in partial to the lack of genetic tools in which to manipulate the bacteria for 
investigations. But with recently adapted methods, genetic investigations will soon 
exponentially increase in the chlamydial field.  
In terms of inclusion membrane protein conservation, in the past, it was found in 
silico that Incs possess a 40 amino acid hydrophobic domain that was used to predict for 
approximately 60 Incs (Bannantine et al., 2000; Li et al., 2008; Scidmore-Carlson et al., 
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1999). In an investigation performed by Weber et al., it was found that there was a 
conservation of Incs specifically between C. trachomatis serovars L2, A and D. There are 
at least 7 known orthologs of C. trachomatis which possessed N or C- terminal 
truncations or frameshift mutations: CT036, CT115, CT179, CT192, CT226, CT300 and 
CT383.  In the study performed by Weber et al. it was additionally found that there was a 
preservation of Chlamydial protein CT228 amongst all three strains tested showing great 
conservation (Weber et al., 2015; Dehoux, et al., 2011; Shaw et al., 2000).  
II. E. Host Cell Exit 
 For a successful and productive intracellular bacterial infection, two things are 
necessary: bacterial entry and bacterial exit.  While C. trachomatis is observed to always 
be endocytosed into the cell, the mechanism of host cell exit is unique. The bacterium 
may exit the host cell by one of two mechanisms, lysis or extrusion. The mechanism of 
lysis involves the systematic permeabilization of membranes whereas extrusion has been 
described as a packaged release of the chlamydial-filled inclusion, encased in the host 
cell membrane (Rocket et al., 1996). C. trachomatis my exit by either mechanism, but 
some unique differences in species exist when it comes to exit (Hybiske & Stephens, 
2007).  C. trachomatis serovars L1-L3 and C. muridarum strains tend to favor lytic 
escape whereas the C. trachomatis serovars A-K preferably exiting by extrusion (Todd & 
Caldwell, 1985). More recently, the once unknown release mechanisms of C. trachomatis 
have been investigated and defined, allowing for great insight into chlamydial biology 
and pathogenicity.   
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The mechanism of lytic host cell escape consists of an ordered distinct sequence 
of events: inclusion membrane permeabilization followed by nucleus permeabilization 
and lastly, plasma membrane permeabilization (Hybiske & Stephens, 2007). In recent 
times, Yang et al. demonstrated that the chlamydial plasmid dictates lytic escape. The 
chlamydial plasmid carries eight genes, one of which is Pgp4. Pgp4 is a known 
transcriptional regulator of several chromosomal genes required for the lytic host cell 
exit.  Furthermore, it was also shown that the T3SS is required for Pgp4 regulated lytic 
escape. While the mechanism for the process is still unknown, partly due to the lack of 
identifying the T3S effector protein, the description of chlamydial lytic escape provides 
further support of the organism to manipulate the cytoskeleton during an active infection 
(Yang et al., 2015).  
The chlamydial host cell exit mechanism of extrusion involves a highly dynamic 
pathway.  Lutter et al. describes that the extrusion host escape is reliant upon an 
interaction between a subunit of myosin phosphatase and the chlamydial inclusion 
membrane protein, CT228. Chlamydial gene CT228 is 588 base pairs in size and is 
reported to be conserved within C. trachomatis serovars A, D and L2 (Weber et al., 
2015). CT228 is translated into a 196 amino acid protein. Based on Kyte & Doolittle 
hydrophobicity plot analysis, CT228 contains two distinct hydrophobic domains spanning 
from position 36 to 58; and from 68 to 86 (Appendices: Figure 1). Thus, warranting 
confidence that CT228 is an inclusion membrane protein fitting current predictions of 
Incs (Weber et al., 2015). The most closely related species of C. trachomatis is known to 
be the recently reclassified C. muridarum, which in the past was known to be a strain of 
C. trachomatis (Ramsey et al.,2009) . In terms of conservation, CT228 amino acids are 
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conserved when comparing of C. trachomatis and C. muridarum, by a sequence 
similarity of 53% (Appendices: Supplemental Figure 2). Upon investigations to 
determine what host cell protein interacts with CT228 during infection, Lutter et al. 
reported that CT228 interacts with a component of myosin phosphatase, MYPT1, during 
infection to regulate the host cell exit mechanism of extrusion (Lutter et al., 2013). Due to 
CT228 localization to the inclusion membrane, interaction of the two proteins shown by 
immunofluorescent microscopy imagery of MYPT1 recruitment to be at the periphery of 
the inclusion in rich active kinase patches, called microdomains (Mital et al., 2010).  
The extrusion mechanism is also dependent on not only the function of myosin 
phosphatase, but also on the ability of the subunit MYPT1 to enzymatically 
dephosphorylates its substrate, MLC2, myosin light chain 2. MYPT1 enzymatically 
removes phosphate groups from MLC2, which dictates overall activity of MLC2.  When 
MLC2 is in a phosphorylated active state, myosin IIA and myosin IIB associate with 
MLC2 to form an active myosin motor complex and the extrusion mechanism of host cell 
exit is preferred. However, when MLC2 is in a dephosphorylated inactive state, the 
correlation toward the host cell exit mechanism of lysis is observed.  Upon interaction of 
MYPT1 with CT228, MLC2 is retained in an active phosphorylated state, thus preferring 
extrusion (Lutter et al., 2013). The protein interaction affecting the extrusion dynamic is 









Figure 1. Dynamic of Host-Cell Exit by MYPT1 interaction with CT228.  
Dephosphorylated MLC2 (inactive) correlates with the host cell exit mechanism of lysis. 
However, phosphorylated MLC2 may interact with myosin IIA and myosin IIB to form 
the myosin motor complex which correlates with the host cell exit mechanism of 
extrusions.  The phosphorylation state of MLC2 dictates overall activity which is 
controlled by MYPT1, a subunit of myosin phosphatase.  MYPT1 will enzymatically 
dephosphorylate the substrate MLC2 under normal conditions. However, Chlamydia is 
known to recruit MYPT1 through interaction with CT228, and deactivate MYPT1.  The 
reasons as to why Chlamydia would recruit and deactivate a protein are still an unknown 
topic for future discussion.  
II. F. Development of Genetic Tools 
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Until recently, Chlamydia trachomatis has remained intractable in terms of 
genetic manipulation.  The pathogen is largely hindered by the genetic methods in which 
to study and manipulate them.  Only recently, in 2011, was it described by Wang et al. 
that these obligate intracellular pathogens could undergo transformation, as demonstrated 
by C. trachomatis serovar L2 transformation with a modified serovars E plasmid (Wang 
et al., 2011). Further provided from this study was the methods and knowledge of foreign 
genes being functionally expressed in C. trachomatis, which provided the platform for 
numerous research groups to begin researching chlamydial growth during infection. For 
example, the approach of chemical mutagenesis was adapted, but as a drawback, this 
method often resulted in undesired secondary mutation sites (Nguyen & Valdivia, 2014; 
Demars et al., 2007; Kari et al., 2011). Though this approach is effective, it is quite costly 
and widely time consuming. Further creating difficulty is that the mutations due to the 
chemical mutagenesis are often random in nature; making this approach less optimal for 
many investigations Current mutagenesis methods by Mueller & Fields utilizes  a 
reporter system for assessment of chlamydial protein secretion which allows for an easily 
adaptable identification of novel secreted proteins (Mueller & Fields, 2015).This 
expression of recombinant gene products is stable as well as direct, making this new 
method ideal for more sophisticated studies (Mueller & Fields, 2015). In 2013, 
Wickstrum et al. described the creation of a tetracycline repressor controlled shuttle 
vector, shown to be successful for controlled gene expression (Wickstrum et al., 2013).  
However, this technology failed to localize expressed proteins appropriately in the host 
cell, as toxicity was noted in several constructs (Wickstrum et al., 2013). This was a 
limitation until the field was further advanced by the description from Bauler et al. of 
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recombinant proteins being expressed either conditionally or constitutively, as dictated by 
promotor control of a uniquely designed shuttle vector system (Bauler et al., 2014). 
Uniquely, the shuttle vector was not only capable of expressing recombinant inclusion 
membrane proteins and effector proteins, but was successful in the appropriate 
localization of such proteins.  
Further developing the field, in 2011, Johnson and Fisher describe an alternative 
method utilizing mobile group II introns to create selectable and targeted chromosomal 
mutations (Johnson & Fisher, 2013). Mobile group II introns exist in an approximate 
quarter of bacterial genomes. These mobile group II introns move between genes in a 
retrotransposition mechanism typically consisting of interactions from an intron encoded 
protein (IEP) possessing an RNA maturase, endonuclease, and reverse transcriptase 
(Lambowitz & Zimmerly, 2004). Intron, non-coding regions of an RNA transcript, 
recognition is based upon sequence recognition between the intron and targeted gene. 
This results in the insertion of the intron into the resulting target gene in a site dependent 
manner.  Prior to the intron splicing event, the intron is stably inserted into the DNA and 
in transcriptional events, excised out of the RNA, and results in a wild-type transcript and 
no change in gene function (Johnson & Fisher, 2013).  
This method was provided from the work with the intron L1.  LtrB from 
Lactococcus lactis and the targeting of genes of interest by changing the intron 
recognition sequences, which allows for base pair recognition and insert into newly 
targeted gene areas (Perutka et al., 2004). The method is made possible through 
algorithms predicting for optimal base pairing and intron modification and retargeting is 
performed by PCR-based modifications.  In trans expression of the gene is subsequent 
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after removal from the intron, which prevents restoration of the gene function via RNA 
splicing in post-transcriptional events.  To prevent gene restoration via post-transcription 
RNA splicing events, the gene is removed from the intron and expressed in trans. This 
method is as follows: removal of the IEP, allowing for the intron to carry alternative 
genes, including a selection cassette.  ltrA and the intron are provided to the bacterium on 
a plasmid.  Expression of the intron and ltrA leads to the subsequent insertion of the 
plasmid into the desired site of the target gene.  After successful insertion, the intron 
donor plasmid is cured leading to the ultimate absence of LtrA and further prevention of 
intron splicing, thus insertional gene inactivity.  
 This method and technology is marketed as TargeTronTM by Sigma.  This system 
was successfully employed in a variety of Gram positive and negative bacteria.  Not only 
Gram negative bacteria, but even an obligate intracellular pathogen, Ehrlichia chaffeensis 
was shown to utilize this technology for directed gene inactivation (Cheng et al., 2013).. 
With this adopted technology, Johnson and Fisher demonstrated the inactivation of an 
inclusion membrane protein incA. With the investigation, it is now supported that with 
this technology, adaptation is ideal for the generation of chromosomal mutations in C. 
trachomatis.  This is very novel in the chlamydial field, as the incA:GII(bla) mutant, as 
established from Johnson and Fisher, was the first site-specific chromosomal gene 
inactivation in the genus Chlamydia (Johnson & Fisher, 2013).  
II. G. Murine Model 
In respect to infection models, the murine model is the most commonly utilized 
animal for chlamydial investigations (De Clercq et al., 2013). Despite the utilization of 
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past animal models in chlamydial infections; such as guinea pigs, non-human primates, 
swine, rabbit and rats, the murine model possesses numerous benefits for usage (Barron 
et al., 1981; Tuffrey & Taylor-Robinson, 1981; Mount et al., 1972; Mount et al., 1973; 
Patton et al., 1983; Patton et al., 1987; Vanrompay et al., 2005; Kaushic et al., 1998; 
Patton et al., 1982). 
Advantages as to utilizing the murine model include: mouse genital tract 
susceptibility to infection with C. trachomatis and C. muridarum, small size and ease of 
handing as well as a low cost (Barron et al., 1981; Tuffrey & Taylor-Robinson, 1981). 
Following vaginal inoculation, mice typically resolve chlamydial infection within 4 
weeks post-infection. However, a few considerations are to be made: the mice strain, the 
dosage of inoculum, age of the animal and hormone levels.  Following bacterial clearing, 
mice possess adaptive immunity that prevents against reinfection (Barron et al., 1981). 
C3H murine strains show a severe course of disease and high rate of infertility when 
compared to other murine strains, due to their lack of innate immune response (de la 
Maza et al., 1994; Bernstein-Hanley et al., 2006). The inoculating dosage of chlamydial 
bacterial load affects the time course of infection and the ascension into the higher 
reproductive tract (Maxion et al., 2004). The utilization of depo-provera prior to murine 
infection was adapted due to the finding of the various stages of the estrous cycle 
affecting susceptibility to MoPn vaginal infection (Pal et al., 1998; Kita et al., 1989). This 
pretreatment alters hormone balance preventing hormonal contributions to the clearing of 
the infection (Tuffrey & Taylor-Robinson, 1981). Furthermore, older murine strains are 
not as easily infected as their younger counterparts (Pal et al., 2001).  In comparison of C. 
muridarum and C. trachomatis infections, C. trachomatis is highly dependent on 
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progesterone pretreatment to establish initial infection compared to C. muridarum 
(Tuffrey & Taylor-Robinson, 1981; Ramsey et al., 1999).  
C. trachomatis is capable of murine infection when administered intravaginally.  
Typical of C. trachomatis murine infection is the observation of quickly resolving genital 
tract infection (Tuffrey et al., 1981). Comparatively, some C. trachomatis serovars, both 
ocular and genital, require a higher bacterial load to establish an infection when 
compared to C. muridarum (Ito et al., 1990; Darville et al., 1997).  
Murine C. trachomatis direct ovary infections inflict post-infection sequelae: 
hydrosalpinx and infertility. However, when C3H/HeJ mice are utilized, a naturally 
ascending infection resulting in salpingitis was observed in some studies (Sturdevant et 
al., 2010).  
Collectively, investigations into the protective immune response brought on by C. 
trachomatis infection within the murine model have been contradictory (De Clercq et al., 
2013).  The innate immune response is enough alone to eradicate C. trachomatis 
infection, as some studies have shown that in the absence of the adaptive immune system 
an infection may resolve (Tuffrey et al., 1982; Perry et al., 1999; Brunham & Rey-
Ladino, 2005; Hafner et al., 2008; Gondek et al., 2012). In addition to the contradictory 
findings within the immune response, there are also differing characteristics amongst C. 
trachomatis strains upon murine infection (Ito et al., 1990).  These discrepancies assist in 
portraying that C3H mice are ideal for C. trachomatis murine infection, as other murine 
strains are not as susceptible to infection (Lyons et al., 2005).  
C. muridarum, MoPn, was previously classified as a C. trachomatis mouse 
biovar. Originally, C. muridarum was isolated from the lungs of mice and upon vaginal 
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inoculation acute genital tract infection resulted (Nigg, 1942).  The observed acute genital 
tract infection in mice resembled genital infections in female humans and assisted in 
establishing the murine model as the choice for chlamydial investigations (Barron et al., 
1981).  
Mice which are infected with MoPn are typically administered the bacterial load 
in an intravaginal route. However, an alternative approach to infect the upper genital tract 
to increase genital tract pathology to closer resemble human infection exists. This 
approach involves infecting the upper genital tract directly, at the ovarian site. However, 
this route of administration is atypical of the natural route of infection transmission 
(Swenson et al., 1983; Farris & Morrison, 2011).  
Vaginal inoculation of mice with C. muridarum results in the recruitment of B 
cells, CD4+ T cells and CD8+ T cells to the genital tract. CD4+ T cells, responsible for 
protective adaptive immunity, with respect to the mouse MoPn infection model, are 
predominantly present through the infection time course (Morrison & Morrison, 2000; 
Igiesterne et al., 1993).  However, CD4+ T cells are not solely responsible for the 
adaptive immunity observed with MoPn mouse infection. Two additional Th1 cytokines, 
interleukin-12 and gamma interferon, also contribute to the adaptive protective immune 
response (Rank et al., 1992; Perry et al., 1997). In regards to primary infection 
eradication of bacteria, it was found that B cells not only are necessary for clearing but 
moreover, they also have a role in the resistance of secondary infection (Ramsey et al., 








III. A. Production of Chemically Competent DH5α and ER2925 Escherichia coli 
 To prepare chemically competent DH5α and ER2925 Escherichia coli, glycerol 
frozen bacterial stocks were struck out with a sterile wooden stick by quadrant streaking 
onto fresh LB agar plates. DH5α E. coli were used to propagate plasmids quickly, mostly 
for sequence verification following cloning procedures.  ER2925 E. coli were used for 
the production of both adenosine and cytosine methylation deficient (dam- and dcm-, 
respectively) plasmid products.  In the genome of C. trachomatis, there is a lack of genes 
encoding for methyltransferases. The result is a low efficency bacterial transformation of 
C. trachomatis if a methylated plasmid product is used. For these resasons, C. 
trachomatis was transformed solely with plasmids which were dam- and dcm- deficient 
(Stephens et al., 1998), Plates were incubated inverted at 37°C over night.  A single 
isolated colony forming unit was used to aseptically inoculate a 5 mL sterile, RNase and 
DNase-free, polystyrene tube of sterile LB broth.  Tubes were incubated over night at 
37°C shaking at 220 RPM.
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The following morning, 250 mL of sterile LB broth was aliquotted into a 
sterilized Erlenmeyer glass flask.  Two and one half mL of LB broth grown culture was 
aseptically pipetted into the Erlenmeyer glass flask, filled with 250 mL of LB broth 
(1:100 dilution).  Prepared cultures were returned to the 37°C shaking incubator until the 
O.D.600 was approximately 0.5-0.8, at which point, flask filled cultures were placed on 
ice to slow growth until further downstream processing, all future steps were performed 
on ice.  Cultures were divided equally, checked by weight, into two sterilized, pre-chilled 
250 mL centrifugation bottles. Next, centrifugation was performed at 4000 RPM for 10 
minutes at 4°C.  Supernatant was poured from cell pellets aseptically.  The residual cell 
pellet was resuspended in80 mL of ice cold, pre-chilled TB buffer (80 mL for every 250 
mL of culture[10 mM Pipes, 55mM MnCl2, 15mM CaCl2, 250 mM KCl]) and incubated 
on ice for 10 minutes.  Centrifugation was then performed again at 4000 RPM for 10 
minutes at 4°C.   Once again, supernatant was discarded aseptically and cell pellets were 
resuspended in 20 mL of ice cold TB buffer (20 mL for every 250 mL of original 
culture).  With a gentle swirl, 1.4 mL of DMSO was added to 20 mL of the TB buffer cell 
suspension to achieve a final concentration of 7%.  Bacterial cultures were incubated on 
ice for 10 minutes. Pre-chilled, sterilized RNase and DNase-free 1.5 mL tubes were then 
filled with approximately 200 µL of chemically competent E. coli and flash frozen for 
approximately 1 to 2 minutes by submersion into an approximate 1:1 mixture of absolute 
ethanol to dry ice.  Tubes were then immediately placed at -80°C freezer for long term 
storage.  
III. B. Bacterial Transformation  
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 Five hundred µL aliquots of chemically competent DH5α and ER2925 E. coli 
were stored at -80°C for long term storage until use.  Transformation protocol is as 
follows: cells were thawed on ice for 30 minutes.  Plasmid DNA was added to cells. 
Tubes were gently tapped to mix and incubated on ice for 30 minutes.  Tubes were then 
immediately placed in a 42°C water bath for 30 seconds, and directly then placed back 
onto ice.  Tubes were left on ice for 10 minutes, at minimum, to allow for high stability 
and recovery by adding 750 µL of SOC (2% w/v tryptone, 0.5% w/v Yeast extract, 8.56 
mM NaCl, 2.5 mM KCl, ddH2O to 1L; autoclaved; 20mM glucose).  Tubes were then 
placed in a shaking incubator at 37°C, 220 RPM to allow for outgrowth.  Fifty µL and 
250 µL of transformants were then plated onto LB agar supplemented with antibiotics.  
Plates were inverted and incubated at 37°C overnight.  
III. C. Construction of the TargeTronTM Chlamydia trachomatis serovar L2, CT228 
Mutant 
The CT228 mutant was kindly constructed and provided from Dr. Derek Fisher, 
Southern Illinois University, Carbondale, Illinois. The chlamydial TargeTronTM vector 
pDFTT3(bla) was modified for spectinomycin selection by replacing the bla cassette 
with the aidA cassette (Lowden et al., 2015). The Sigma-Aldrich TargeTronTM algorithm 
was used to predict CT228 insertion sites with lowest E-values to retarget the intron to 
insert, in an antisense orientation, at 295 base pairs (E-value of 0.200). PCR was utilized 
to retarget the vector for insertion into CT228 using Phusion High-Fidelity PCR Master 
Mix (Thermo-Fisher) and primers 228A, 228B, 228C, and EBS universal, followed by 
DNA restriction endonuclease digestion as previously described (Johnson & Fisher, 
2013) (Table 1). The vector was transformed into E. coli DH5α and grown at 37°C in 
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Luria Bertani (LB) media supplemented with 20 µg/ml chloramphenicol. C. trachomatis 
transformation and antibiotic selection with 500 µg/ml spectinomycin was performed as 
adapted from Lowden et al.  Mutants were plaque purified through a series of passages to 
obtain a passage 4 clonal CT228::GII(aadA) final resulting CT228 mutant strain, 
ΔCT228. The isolate was then expanded in L2 mouse fibroblasts and stored in 1X SPG 
buffer (10 mM sodium phosphate [8 mM Na2HPO4-2 mM NaH2PO4], 220 mM sucrose, 
0.50 mM l-glutamic acid) at -80°C.  
III. D.  PCR validation of the CT228 Mutant 
Genomic DNA (gDNA) was extracted from wild type (L2) and CT228 mutant EB 
(DFC14) stocks using a DNeasy Blood and Tissue Kit (Qiagen). PCR reactions were 
performed using 50 ng of gDNA or 5 ng of plasmid DNA and Phusion High-Fidelity 
PCR Master Mix. PCR products were subjected to agarose gel electrophoresis, stained 
with ethidium bromide and visualized by UV transillumination. To confirm GII insertion, 
the amplicon produced from PCR reactions using primers CT228F and CT228R (Table 
1), was agarose gel purified using the GeneJET gel extraction kit (Thermo-Fisher) and 
ligated into pJET (Thermo-Fisher) to generate pJET::CT228GIIaadA. Resulting products 
were then transformed into E. coli DH5α and transformants were selected by antibiotic 
selection using LB agar supplemented with 100 µg/ml of ampicillin. A single colony was 
then selected for by overnight growth in LB broth medium supplemented with ampicillin 
and resulting plasmids were extracted using the GeneJET Plasmid Miniprep kit (Thermo-
Fisher). Gene insertion in pJET::CT228GIIaadA was sequenced with primers JETF and 
JETR (Table 1) via Sanger sequencing performed by Macrogen USA. Obtained 
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sequences were analyzed using BioEdit (TA Hall 1999) and Clone Manager (Sci-Ed 
Software). 
III.  E. Recombinant DNA Procedures 
The complemented CT228 mutant was created by the following procedures. The 
vector, pBOMB4R (Bauler & Hackstadt, 2014) was kindly provided by Dr. Ted 
Hackstadt, National Institutes of Health Rocky Mountain Laboratories, Hamilton, 
Montana. pBOMB4R is a shuttle vector composed of a fragment of the native chlamydial 
plasmid, an rpoB promotor, a multiple cloning site for directional insertion and two 
origins of replication  (Bauler & Hackstadt, 2014). The green fluorescent protein (GFP) 
contained within pGFP:SW2 was replaced with the mCherry gene, amplified from 
pmCherry-C1 vector (Clontech). The vector, received on filter paper, was extracted with 
water. One µL of vector was transformed into DH5alpha E. coli and plated onto Luria-
Burtani (LB) agar plates containing 100 ug/mL carbenicillin. Clones were picked into 5 
mL of broth LB supplemented with 100 ug/mL carbenicillin and grown over night at 
37°C and shaking at 220 RPM. Plasmids were extracted with the aid of ZyppyTM 
Plasmid Miniprep Kit (ZymoResearch) and checked for quality by 0.8% gel agarose 
electrophoresis. Plasmids were then subjected to recombinant procedures by the 
following: 30 µL of total pBOMB4R vector was digested with 5 µL of buffer 1.1 (NEB), 
1 µL of KpnI (NEB) and 1 µL BamHI-HF overnight in a 37°C  water bath in 600 µL 
tubes.  One µL of Antarctic phosphatase (NEB) was added to the digestion reactions and 
was allowed to incubate at 37°C  for two more hours.  Digestions were purified by DNA 
Clean & ConcentratorTM Kit (ZymoResearch) and eluted in 200 µL of DNase RNase free 
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H20.  Five µL of the purified vector was checked by 0.8% agarose gel electrophoresis. 
Vector was stored at 4°C until usage.  
Full length CT228 constructs were prepared by the following procedures. 
Polymerase Chain Reactions were set up as follows: 1 µL of primer CT228pBOMBKpnI 
and 1 µL of primer CT228BOMBBamHI-3 (see in Primer table), 1 µL L2 gDNA from C. 
trachomatis serovar L2 gDNA (Quick-gDNA™ MiniPrep ZymoResearch and 45 µL of 
Platinum PCR Supermix High Fidelity (Invitrogen) were mixed on ice. Polymerase chain 
reaction cycles were as follows: 95°C  for 2 minutes initial denaturing, 95°C  for 30 
seconds, 52°C  for 30 seconds and 68°C  for 1 minutes 30 seconds for 35 cycles along 
with a 5 minute 68°C final elongation period.  Two µL of PCR amplicons were checked 
by 0.8% agarose gel electrophoresis. The Polymerase Chain Reaction amplicons were 
subjected to the Clean & ConcentratorTM Kit (ZymoResearch) and purified products were 
digested as follows: 1 µL BamHI-HF (NEB) and 1 µL KpnI (NEB) and 2.5 µL of buffer 
1.1 (NEB) were added and mixed in 600 µL tubes, placed in a water bath set at 37°C 
overnight. Resulting digests were cleaned once again using the Clean & ConcentratorTM 
Kit (ZymoResearch) and checked for purity by 0.8% agarose gel electrophoresis.  
Ligation reactions were as follows: 4 µL of amplicon was added with 1 µL of the vector 
(diluted 1:20 in water) along with 5 µL of 2X Ligation Buffer (NEB) and 1 µL of Quick 
Ligase (NEB). Reactions were allowed to incubate at room temperature for 30 minutes.  
The reaction was then transformed into NEB Turbo E. coli.  Then after sequence 
confirmation, the plasmid was transformed into a methylation deficient strain of E. coli 
ER2925, (see bacterial transformation section) to serve for bacterial transformation into 
the TargeTronTM CT228 mutant of C. trachomatis. Transformants were then plated onto 
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LB agar supplemented with 100 ug/mL carbenicillin and grown inverted, overnight at 
37°C.  Clones were picked and grown in LB liquid broth supplemented with 100 ug/mL 
carbenicillin overnight at 37°C shaking at 220 RPM.  Plasmids were extracted with the 
aid of ZyppyTM Plasmid Miniprep Kit (ZymoResearch) and eluted in 45 µL. Five µL of 
the complementation plasmid was then subjected to restriction endonuclease digestion as 
follows: 5 µL of DNA, 17.5 µL H2O, 2.5 µL buffer 1.1, 0.5 µL KpnI and 0.5 µL BamHI-
HF were added together. Reactions were incubated in a water bath at 37°C to incubate for 
a total of 4 hours.  Entire reactions were assessed by 0.8% agarose gel electrophoresis for 
appearance of both insert at approximately 600 bp and vector at approximately 10.7 kb. 
After gel confirmation, 10 µL of the product was sent for sequencing using an Applied 
Biosystems 3730 DNA analyzer, courtesy of OSU Core Facility. After sequence 
confirmation and confirmation of correct frame insertion (DNAMAN), the 
complementation plasmid was then transformed into C. trachomatis CT228 mutant strain, 
DFCT14 (see section chlamydial transformation) producing the complementated CT228 
mutant: ΔCT228C.  
III. F. CT228 Mutant Transformation with the CT228 Complementation Plasmid 
After DNA sequence confirmation provided by the OSU Core Facility 
(DNAMAN), the constructs were transformed into CT228 mutant strain, ΔCT228 of C. 
trachomatis serovar L2.  Plasmid DNA (3µg) was incubated with mutant density gradient 
purified EBs and 40 µL of CaCl2 buffer (50 mM Tris; 250 mM CaCl2) for 30 minutes at 
room temperature (Wang et al., 2011; Song et al., 2013; Agaisse & Derré, 2013; Bauler 
& Hackstadt, 2014). After 30 minutes, cold RPMI 1640 + 10% FBS was added and 
bacteria were plated into three HeLa 229 cell confluent monolayers seeded in a six-well 
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plate.  Cultures were incubated at 37°C with 5% CO2. To produce passage 1, at 36-40 
hours post infection, wells were removed of media and scraped after applying cold sterile 
distilled water to lyse host cells. The lysed supernatant was centrifuged at 1500 RPM for 
5 minutes and supernatant was combined with 1 mL of RPMI 1640 + 10% FBS to infect 
a fresh monolayer of confluent HeLa 229 cells.  Six well plates were centrifuged at 700X 
g for 1 hour. Media was removed and replaced with 1 mL of RPMI 1640 + 10% FBS 
supplemented with 1 ug of cyclohexamide/ml and 0.1 U of Penicillin G/ml and incubated 
for 40 hours.  To produce passage two, at 36-40 hours post infection, wells were removed 
of media and scraped after adding cold sterile distilled water to lyse host cells.  Lysate 
was collected and spun at 1500 RPM for 5 minutes and the supernatant was combined 
with 2 mL of RPMI 1640 + 10% FBS and used to create a series of dilutions (10-17). 
Three new 24 well plates of confluent monolayer of HeLa 229 cells were then infected 
with supernatant from passage two to produce passage three.  Plates were centrifuged at 
700X g for 1 hour and then lysate was removed and cell monolayers were overlayed with 
a mixture of 1.1% agarose  (sterilized and at 42°C) + 2X RPMI1640 (42°C) + 1ug/mL 
cyclohexamide.  Overlays were allowed to solidify for approximately 10 minutes.  RPMI 
1640 + 10% FBS + 1:1000 cyclohexamide and 0.1U Penicillin G was then applied to the 
surface of the agarose overlay and allowed to incubate for 5 days, replacing media every 
2 days including cyclohexamide and 0.1 U Penicillin G for consistent selection. For 
expansion of clones, individual plaques were punched with sterilized, scissor cut P-1000 
pipette tip and placed into a 1.5 mL eppendorf tube. One mL of RPMI 1640 + 10% FBS 
was then added and sample was vortexed for 1 minute.  The entire volume was then 
placed into a T25 flask onto a confluent layer of HeLa 229 cells. At 6 hours post 
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infection, media was replaced with RPMI 1640 + 10% FBS + 1 mg/mL cyclohexamide 
and 0.1 U of Penicillin G for selection.  Clones were allowed to grow for 72 hours and 
were then frozen as a backup stock in 1X SPG buffer at -80°C.  Frozen plaque purified 
clones were then used as a crude preparation of EBs to infect confluent HeLa 229 cell 
monolayers for immunofluorescent microscopy analysis and molecular methods.   
III. G. Immunofluorescent Analysis 
HeLa 229 cells were seeded onto glass cover slips in 24 well plates and grown to 
70% confluency.  Cells were infected with C. trachomatis serovar L2 mutant CT228 EBs, 
C. trachomatis serovar L2 EBs and C. trachomatis serovar L2 CT228 mutant 
complementation EBs in cold RPMI 1640 + 10% FBS using crude stocks diluted in ice 
cold RPMI 1640 supplemented with 10% FBS.  Infections were allowed to incubate for 
24-36 hours post-infection at which point cell monolayers were fixed in methanol, rinsed 
with 1XPBS three times, 5 minutes each wash, blocked with 2% BSA-PBS for one hour, 
rinsed 1 time for 5 minutes. Samples were then stained with indicated primary antibodies 
(See below) for a period of one hour at room temperature, rinsed with 1X PBS 3 times, 5 
minutes each and stained with fluorescent secondary antibodies  (See below) for a period 
of 1 hour at room temperature until rinsing, once again 3 times, 5 minutes each rinse. 
Round glass cover slips over slips were then mounted (Dako Mounting Media) onto glass 
slides and visualized with a Leica DMI600B inverted microscope with objectives 40X 
and 63X with oil.  Images were edited for only size and color using Adobe Photoshop.  
The following antibodies were then prepared in 2% BSA: anti-L2 EB antisera 
(Generously provided from the Hackstadt lab National Institutes of Health Rocky 
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Mountain Laboratories); Anti-MYPT1 (US Biologic, Danvers, MA); Anti-phospho 
(pSer-19)-MLC2 was purchased from Abcam (Cambridge, MA); Anti- Src-pTyr419 
(clone 9A6) (Millipore, Billerica, MA) was used to detect active Src-family kinases; 
Anti-Chlamydia LPS (Cell signaling, Danvers, MA); Anti-myosin IIA and anti-myosin 
IIB were purchased from Thermo Scientific (Thermo Scientific, Rockville, MD); Anti-
mouse or anti-rabbit DyLight 594 and DyLight 488 (Jackson ImmunoResearch 
Laboratories, West Grove, PA) were used as secondaries.  
III. H. CT229-CT224 Operon Expression Assessment 
 RT-PCR was used to rule out possible polar effects in the CT228 mutant.  HeLa 
229 cells were seeded into 24 well plates and grown to 70% confluency.  Cells were 
infected to an MOI of 1 with C. trachomatis serovar L2 mutant CT228 EBs or C. 
trachomatis serovar L2 EBs in cold RPMI 1640 + 10% FBS.  Infections continued until 
the point of RNA extraction using Trizol and the Direct-zol RNA kit (ZymoResearch) at 
2, 4, 8, 12, 24 and 48 hours post-infection. An in-column digestion was performed using 
DNase, (Roche) and purified RNA was checked for genomic DNA contamination by the 
use of PCR, amplifying with internal gene primers of CT229, at which point samples 
were subjected to a second DNase treatment using the DNase I Kit (Roche), and checked 
once again by PCR before continuing to cDNA synthesis. After confirming an absence 
genomic DNA contamination, quality by gel electrophoresis and quantitation was 
performed using UV spectrophotometry.  cDNA synthesis was performed with use of 
Maxima H Minus Reverse Transcriptase (200 U/L) (ThermoFisher).  One pg-5pg of 
cDNA (or 1 µL of H2O, for the negative control) was used for each reaction. One 
hundred pmol of random hexamer primer and 0.5 mM dNTPs were used as well. 
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Volumes of each reaction were filled with DNase RNase free water until 15 µL total.  
Reactions were mixed and then centrifuged for 15 seconds. Following centrifugation, 
reactions were incubated at 65°C for 5 minutes to remove possible secondary structures 
and then chilled on ice again for several minutes. Four µL of 5X reverse transcriptase 
buffer (ThermoFisher) was added to each reaction.  Reactions were mixed gently and 
centrifuged for 15 seconds.  Reactions were incubated for 10 minutes at 35°C, 30 minutes 
at 60°C , and 5 minutes at 85°C . The successful production of cDNA was checked for by 
gel electrophoresis.  A series of PCRs were set up to ensure expression of each gene 
within the CT229-CT224 operon with the use of internal gene specific primers (Table 1) 
and run on a 0.8% agarose gel for evaluation of gene expression.  
III. I. Western Blot Analysis  
A 24-well plate of confluent HeLa 229 cells was infected at an MOI of 
approximately 1 with wild type, C. trachomatis serovar L2, CT228 mutant and CT228 
complementation EBs. At 36 hours post-infection, cell monolayers were removed of 
supernatant and lysed in 200 µL of Laemmli buffer (Laemmli, 1970) supplemented with 
5% beta-mercaptoethanol. Twenty µL of heated (99°C for 4 minutes) protein extracts 
were separated by SDS-PAGE (10% resolving gel; 85 V for 3 hours) (and transferred to 
nitrocellulose membrane (125 V for 45 minutes) in transfer buffer (100 mL 10XTris/Gly-
SDS Buffer, 200 mL methanol, 700 mL diH2O).  Samples were blocked in 5% skim milk 
in 2%BSA-PBST buffer (8mM Na2HPO4, 150mM NaCl, 2mM KH2PO4, 3mM KCl, 
Tween-20 pH 7.4) and incubated over night with in primary antibodies with constant 
agitation (anti-CT228) in blocking buffer.  Blots were washed 3 times at room 
temperature with PBST, the first for several seconds and the following 2 for 15 minutes 
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each.  Blots were then incubated in corresponding HRP-conjugated donkey anti-rabbit 
IgG secondary or HRP-conjugated donkey anti-mouse IgG secondary diluted antibodies 
(Cell Signaling) for 1 hour at room temperature with constant agitation. Blots were then 
rinsed 3 more times, 5 minutes each rinse at room temperature, with PBST.  Blots were 
then drained of PBST and developed using equal parts reagent A and reagent B of 
VisiGlo ECL Western blotting detection reagents (Amresco). Samples were then exposed 
for 1-3 minutes (ECL Detection machine in NRC). 
III. J. Mice Selection  
  Six week old female inbred C3H/HeJ mice were purchased from Jackson 
Laboratories (Bar Harbor, Maine) and divided into four groups (n=15 each) and mice 
were assigned for infection:  SHAM, Chlamydia trachomatis serovar D/LC, C. 
trachomatis serovar L2, C. muridarum mouse pneumonitis (MoPn). C3H/HeJ mice 
contain a mutation in the TLR4 response locus, making mice susceptible to infection by 
Gram-negative bacteria due to the innate immune system defect of failure to recognize 
and bind endotoxin. After arrival, mice were allowed to acclimate to the new 
environment several days prior to the experiment. Four additional mice were also used 
strictly for extrusion assessment. 
III. K. Cell Strains Used for Murine in vivo Experiments 
Confluent HeLa 229 cell (ATCC) monolayers were used for assessment of recoverable 
infectious forming units by dilution and plating techniques in 24 well plates.  Cells were 
overlayed with RPMI 1640 + 10% fetal bovine serum and 1ug/mL cyclohexamide as 
needed.  C. trachomatis serovar D/LC (a late clearing, phenotypic strain of serovar D) 
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was kindly provided from Dr. Harlan D. Caldwell (Rocky Mountain Laboratories, 
National Institutes of Health, Hamilton, MT).   
III. L. Murine Estrous Synchrony 
To synchronize estrous of all female inbred 6 week old mice (Jackson Laboratories), 
mice were sedated individually at a flow rate of 1.5L/minutes O2 with 3% isoflurane 
(Henry Schein). Individual mice were subcutaneously administered 150 mg/mL or 20 uL 
of Depo provera (Pfizer) (29G X ½’’ needle and 3/10 mL insulin syringe Covidien 
Monoject™) at the nape of the neck while the mouse was held flat in a prone position. 
Mice were then allowed to regain consciousness and returned to cages.  
III. M. Infection of Murine Lower Genital Tracts 
Normalized EB stocks of C. trachomatis serovar L2, and D/LC and C. muridarum MoPn 
were produced to reach a final concentration of 1X106 EBs in 5 µL of 1X SPG buffer (87 
mL (0.2 M Na2HPO4), 13 mL (0.2 M NaH2PO4), 0.72 g L-Glutamic acid, 1 L H2O, pH 
7.4 with NaOH, autoclave sterilize). For control mice, 1X SPG was solely administered.  
Tubes of normalized EBs were kept on ice until infection. All mice were individually 
sedated with 3% isoflurane at a flow rate of 1.5 L O2/minute (Figure 15). The three mice 
groups: D/LC, L2 and MoPn, were vaginally administered 5µL of normalized EBs by 
gentle pipetting into the opening of the vagina. All strains were appropriated normalized 
to 1X106 EBs/5 µL in 1X SPG buffer. Control SHAM mice were administered 5 µL of 
1XSPG.  EBs were normalized as following: 9.2 mL of 1X SPG was added to 5 µL of 
serovar L2 density gradient purified EBs to produce a final concentration of 1X106 EBs/ 
5µL; 8.2 mL of 1X SPG was added to 5µL of concentrated stock serovar D/LC density 
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gradient purified EBs to produce a final concentration of 1X106 EBs/ 5µL; 156 µL of 
MoPn density gradient purified EBs were spun down at 10,000 RPM for 5 minutes, 
supernatant was discarded and pellet was resuspended in 85 µL of 1X SPG to result in a 
final concentration of 1X106 EBs/ 5µL. Sedation chamber and holding chamber were 
bleached between mouse groups to prevent cross-infection.  
III. N. Swabbing of Murine Vaginal Tracts 
 At days 3, 7, 10, 14, 17, 21, 14, 28, and 35 post-infection, mice were swabbed for 
either the assessment of infectious forming units (IFUs) or for extrusion assessment. 
Mice were individually sedated as previously described and held in the downward supine 
position. Mice which were used for the assessment of IFUs were swabbed 8 rotations to 
the right and 8 rotations to the left, and the sample was then placed into 600 µL of 1X 
SPG buffer and 2 sterile glass beads.  Samples were brought to the molecular processing 
laboratory for further testing. Mice which were used for the extrusion assessment studies 
were swabbed as follows: the swab was placed into 100 µL of RPMI1640 (10 L H2O, 
10L pack RPMI, 2.9 g L-glutamine, 1.1 g pyruvic acid sodium salt, 20 g sodium 
bicarbonate, pH 7.0, filter sterilize through 0.2 µm filter) supplemented with 10% fetal 
bovine serum and the swab handle was cut using sterilized scissors (Further description 
in extrusion assessment).  Samples were brought to the molecular processing laboratory 
for further testing.  
III. O. Assessment of Infectious Forming Units 
At days 3, 7, 14, 21, 28 and 35 post-infection, mice were individually sedated 
with 3% isoflurane at 1.5L O2/minute until breathing slowed. Mice were then removed 
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from induction chamber and placed in hand with vaginal opening exposed. Vaginal tracts 
were swabbed 8 rotations to the right and 8 rotations to the left, for each mouse IFUs 
(Puritan HydraFlock Sterile Flocked Collection Devices, Puritan Diagnostics, Gullford, 
Maine).  Independent swabs were added to 1.5mL eppendorf tubes with 600 µL1 X SPG 
and two glass beads, as adopted from previously described studies (Cheng et al., 2008; 
Chen et al., 2014). 
Samples were kept on ice until serial dilution and plating onto HeLa cell 
monolayers.  At days 3, 7, 14, 21, 28 and 35 post-infection, individual samples were 
vortexed for 30 seconds to assist in shedding infectious EBs from swabs. In each well of 
a 24 well plate, 900 µL of 1X Hanks Balanced Salt Solution (HBSS) (Thermo Fisher 
Scientific) was aliquotted. In the first well of the plate, 100 µL of the sample was added 
creating a 10-1 dilution. Mixing was performed by pippetting 10 times into the first well.  
100 µL was then taken up and moved to the next well in the same row, producing a 10-2 
dilution. Contents of well were mixed by pipetting again 10 times. This process was 
repeated for each well of the row until a 10-6 dilution was created. On a separate 24 well 
plate with confluent HeLa cell monolayers, media was removed and 200 µL of each 
corresponding sample dilution was placed onto cell monolayers. Plates were spun at 700 
X g for 1 hour. 1 mL of RPMI 1640 +10% FBS were added to each well after 
centrifugation and plates were then incubated for 24-34 hours at 37°C with 5% CO2.  
All wells were then fixed with ice cold 100%  methanol for 15 minutes.  Wells 
were washed 3 times for 5-10 minutes each time with 1X PBS. Plates were blocked with 
100 µL of 2% BSA made in 1X PBS for 1 hour at room temperature. Samples were then 
stained with 100 µL of 2% BSA-PBS diluted corresponding antibodies for one hour: 1°: 
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anti-D/LC (mouse monoclonal) anti-Mouse pneumonitis (mouse monoclonal) (courtesy 
of Dr. Caldwell); anti-L2 (rabbit polyclonal) [1:1000]; apply 100 µL of 2°: anti-rb488; 
anti-ms594 to corresponding wells (mouse with mouse; rabbit in rabbit [Jackson 
ImmunoResearch Laboratories, Inc.]) [1:1000 and 1:500, respectively]. After samples 
were allowed to block for a period of 1 hour, all wells were rinsed well with 1X PBS for 
a minimum of two times, 5 minutes each rinse. Samples were subjected to fluorescent 
microscopy (10X magnification) for counting.  
A dilution well with IFUs between 20-200 per field of view was used to perform 
counts. Twenty fields of view were counted and recorded, (Microsoft Excel) as well as 
the dilution well for each sample at each sampling time (3, 7, 14, 21, 28 and 35 days post-
infection).   Enumerations and standard deviations were performed with the aid of 
Microsoft Excel (average number of IFUs/well X dilution factor X microscope factor X 
amount plated).  Data was then subjected to the box and whisker graph on Prism 7.0 to 
obtain a comparative analysis of recoverable IFUs verses the days post infection, 
amongst the Chlamydia strains.  
III. P. Extrusion Assessment 
At days 21 and 24 post-infection, mice were individually sedated with 3% 
isoflurane at a rate of 1.5L O2/minute until respiration rate slowed.  Mice were then 
removed from the induction chamber and held during vaginal tract swabbing in which 
swabs were inserted into the vagina and rotated 8 times to the right and 8 times to the left.  
Independent swabs were cut and placed into 1.5 mL eppendorf tubes containing 100 µL 
of RPMI 1640+10% FBS and kept cool until downstream processing for imaging.   These 
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steps were repeated for each mouse until all mice had been sampled. With sterile forceps 
the swabs were rotated 10 times and gently pressed on the rim of the tube exiting, to 
remove any residual media and sample.  Samples were prepared for Confocal microscopy 
as follows: 1 µL of NucBlue® Live ReadyProbes® Reagent (Thermo Fisher Scientific) 
and 1 µL of water solubilized FM®4-64 membrane stain (5µg/mL) (Thermo Fisher 
Scientific) was added to each sample tube. Tubes were flicked gently approximately 5 
times. 10 µL of the sample was then placed on a clean glass microscope slide and a clean 
glass cover slip was placed on top to create a wet mount for microscopy. Samples were 
viewed and photographed with 60X magnification with oil on an Olympus Laser 
Scanning Confocal microscope.   
III. Q. Sera Collection  
At days 7, 35 and 53 days post infection; mice were euthanized to collect sera for 
cytokine and immune system activation assessment. Mice were individually sedated with 
3% isoflurane at 1.5 L/ minute until respiration rate was approximately 20 
respirations/minute.  Cervical dislocation was performed and the mouse was then pinned 
to a dissection plate.  Using a 25 gauge needle and 1 cc syringe, whole blood was 
collected and placed into a 1.5 mL O-ring tube and flicked several times to mix.  Whole 
blood filled tubes were then spun at 600 X g for 10 minutes and stored at -20°C until 
assessment by ELISA (future experiments not included in this thesis).  
III. R. Vaginal Wash for IgA Assessment 
To investigate and compare the secretory IgA immune response amongst 
chlamydial strains, at day 30 days post infection, mice were subjected to a vaginal wash 
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to determine the presence of IgA by several steps. Briefly, 60 µL of 0.5% BSA-PBS 
buffer was introduced to individual mice by pipetting. The sample was refluxed five 
times and transferred, along with any remaining fluid in the vaginal tract, to a 
corresponding 1.5 mL eppendorf tube. This process was repeated once more and 
subsequent samples were kept on ice until spinning at 15,000 rpm for 10 minutes at 4°C.  
Resulting supernatant was removed apart from the pellet and transferred to a new tube 
and frozen at -20°C until further analysis.   
III. S. Gross Physiological Assessment 
To assess the anatomical sequelea following the murine infection, at days 64 and 
65 post infection, remaining mice were sacrificed. Following cardiac puncture and whole 
blood collection, mice were dissected for reproductive tracts: ovaries, oviducts, uterine 
horns, uterus and bladder.  Whole reproductive tracts were photographed next to a 
dissection ruler (VWR) with a 16 megapixel LED flash camera [pixel size 1.12 um, 
manual focus] and images were adjusted for size and color with Adobe Photoshop.  
Reproductive tracts were then sent in formalin solution to OSU Veterinary Medicine for 
histopathological assessment by a trained and licensed Pathologist (results of which are 
not included in this thesis). 
III. T. Murine Cervical Dislocation and Cardiac Puncture 
At the end of the time course, mice were individually sedated, as previously 
described. Mice were cervically dislocated by the following: with the left hand grasp the 
mouse tail ~1/2” from the base, with the right hand thumb and index finger, place onto 
neck region; pull the left hand holding the tail the same time as pressing and pulling with 
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the right hand to dislocate at cervical region. Mouse was pinned at each arm to the 
dissection plate. With a 25 gauge needle and 1 cc syringe (Sur-Vet TerumoR Syringe), the 
needles were inserted at a 30° angle directly under the sternum toward the head.  The 
needle was continued in this motion for ~ ½ of the needle length. At the point of the 
needling approximately ~ ½ the length into the mouse thoracic cavity, the angle of 
insertion of the needle was adjusted to be as close to 0° as possible.  Then, the needle was 
continued into the thoracic cavity to penetrate the heart.  The plunger of the syringe was 
gently pulled every 3 seconds whilst holding a steady grasp on the syringe to extract as 
much whole blood as possible. The needle was removed from syringe in disposal 
container and whole blood was ejected from the syringe into a 1.5 mL O-ring tube, be 
sure to flick tube to disperse anti-coagulant into the sample. Tubes were labeled with 
animal number, date, and chlamydial strain of infection. Carcasses were disposed of into 
biohazard bag (to be bagged up after experiment). Care was taken as to begin with 
SHAM control mice first. Once all mice were sacrificed and whole blood collected, tubes 
were spun at 600 X g for 10 minutes. Sera were collected and frozen at-80°C until use.  
III. U. Dissection of Murine Reproductive Tracts 
 At the end of the time course, following cervical dislocation and cardiac puncture, 
mice reproductive tracts were dissected, photographed and collected for gross and histo-
pathological comparisons, taking care to always begin with SHAM control mice.  Mice 
were pinned to dissection trays, and using dissection scissors and forceps, ovaries, uterine 
horns, uterus and bladder were cut and removed from the mouse. Reproductive tracts 
were then cleaned of any fatty tissue and photographed.  
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III. V. Statistical Analysis 
Statistical analysis (box and whisker plot and two tailed T-test) was performed in 







IN VIVO COMPARISON OF CHLAMYDIAL STRAINS: C. TRACHOMATIS SEROVAR 




Chlamydia trachomatis is the most frequently reported bacterial sexually transmitted 
infection. Even after a C. trachomatis infection is treated, there is an increased risk for 
the development of pelvic inflammatory disease and cervical cancer, but the mechanisms 
are poorly understood. As an obligate intracellular pathogen, C. trachomatis usurps many 
host cell-signaling pathways from within a membrane bound vacuole, called an inclusion. 
C. trachomatis is also known to synthesize and secrete via the type III secretion system, 
inclusion membrane proteins (Incs) that are inserted into the inclusion membrane and 
serve as the interface between Chlamydia and the host. C. trachomatis is the first 
bacterial pathogen observed to recruit myosin phosphatase (MYPT1) for means of host 
cell exit, and does so through the chlamydial Inc protein, CT228. In this study the 
chlamydial TargeTronTM system was used to genetically inactivate CT228 in the C. 
trachomatis genome. TargeTronTM insertion was confirmed by PCR and expression of 
the CT229-CT224 operon of the mutant was verified by RT-PCR to rule out polar effects. 
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The CT228 mutant was verified to be deficient in CT228 production and MYPT1 
recruitment by immunofluorescence.  Genetic complementation of CT228 in trans 
successfully restored MYPT1 recruitment in the mutant. This study demonstrates 
successful gene inactivation of the chlamydial protein CT228, successful 
complementation of the TargeTronTM mutation in trans, and confirms the role of CT228 
in MYPT1 recruitment. Additionally these studies provide a platform to further 
investigate the role of CT228 in chlamydial pathogenesis.  
Keywords 
Need 5 but limit to 8 (Chlamydia, TargeTron, Complementation, MYPT1, CT228)  
Introduction 
Chlamydiae are pathogenic and unique obligate intracellular bacteria that infect a 
wide variety of animals. Chlamydia trachomatis is the causative agent of the number one 
human sexually transmitted infection in the United States. Serovars A-C are ocular in 
nature, resulting in infectious blindness; serovars D-K and L1-L3 are urogenital in nature, 
with L1-L3 resulting in highly invasive LGV (Burton and Mabey, 2009).  
Subsequent to clearing of an infection with antibiotics, an associated risk can be 
observed for the development of numerous sequelea. In developed countries, nearly half 
the incidences of pelvic inflammatory disease are caused by a chlamydial infection 
(Khalaf, 2003). Other complications after an infection include fallopian tube scarring, 
infertility, pelvic inflammatory disease and ectopic pregnancy (Smith et al., 2001).  
Chlamydiae are unique in that they possess a biphasic developmental cycle.  
Upon infection, when the extracellular, non-replicative, infectious elementary body (EB) 
binds to the surface of a host cell, the EB is endocytosed, avoids the endocytic pathway, 
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and establishes a parasitophorous vacuole, deemed an inclusion (Moulder, 1991; 
Hackstadt et al. 1997). The inclusion membrane will serve as the interface between the 
host and Chlamydiae.  From within this inclusion, the EB differentiates into the 
replicative, non-infectious, metabolically active reticulate body (RB). The bacteria 
synthesize a variety of proteins, which are secreted using a type III secretion system.  
Some of these proteins, called inclusion membrane proteins (Incs) decorate the inclusion, 
inserting into the cytosolic face of the inclusion membrane and recruit proteins of the host 
cell for a variety of functions (Rockey et al., 1997; Scidmore & Hackstadt, 2001; 
Hackstadt et al., 1999). At approximately 15 hours post infection, RBs begin to convert 
back to EBs, thus allowing for another cycle of replication. The growing numbers of 
chlamydia fill the host cell causing the cell to swell, and then exit the host cell by either 
one of two mechanisms: lysis or extrusion (Hybiske & Stephens, 2007; Todd & Caldwell, 
1985). 
  Most recently, Yang et al. describe that the mechanism of lytic exit is dependent 
on a transcriptional regulator, Pgp4, encoded on a single plasmid possessed by many 
Chlamydiae (Yang et al., 2015). Whereas, the extrusion mechanism of host cell exit is 
regulated by interactions between host and chlamydial proteins at the site of the inclusion 
membrane. Lutter et al. were the first to describe that a chlamydial inclusion membrane 
protein, CT228, recruits a component of myosin phosphatase, MYPT1, to the inclusion 
during infection.  This interaction between CT228 and MYPT1 was observed to regulate 
the host cell exit mechanism of extrusion (Lutter et al., 2013).  Yet, without further 
characterization of CT228, a greater understanding of how the extrusion method of host 
cell exit impacts chlamydial pathogenesis could not be established.   
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Historically, the chlamydial field of research was greatly limited by the 
availability of genetic tools of which to manipulate the bacterium. The first account of the 
stable introduction and maintenance of foreign DNA in Chlamydia spp. Was reported by 
Binet and Maurelli (Binet & Maurelli, 2009).  Further advancement in the field occurred 
with the development of the chemical transformation and chemical mutagenesis of 
Chlamydia trachomatis (Wang et al., 2011, Johnson & Fisher, 2013; Gerard et al., 2013; 
Kari et al., 2011; Nguyen & Valdivia, 2014).  These findings allowed for a platform for 
which numerous research groups would begin to rapidly investigate chlamydial gene 
function, growth and infectivity. Recent methods allow for the generation of plasmid 
gene knockouts, chemical mutagenesis and plasmid-based gene knock in approaches, but 
the field still lacked tools to target selectable chromosomal mutations. (Gerard et al., 
2013; Kari et al., 2011; Nguyen & Valdivia, 2014) Johnson and Fisher were the first to 
report a selectable site-specific chromosomal gene inactivation of incA in C. trachomatis, 
by the insertion of a group II intron (Johnson & Fisher, 2013). By utilizing a 
commercially available TargeTron TM system (Sigma), the first site-specific gene 
inactivation in Chlamydia was accomplished. Importantly, in the chlamydial-adapted 
TargeTronTM system, complementation in trans has not been published to date. 
As TargeTronTM system success with the inactivation of incA was observed, we 
hypothesized that genetic inactivation of CT228 could be accomplished and that 
complementation could be utilized to restore MYPT1 recruitment to the inclusion during 
infection. To test this hypothesis, the TargeTronTM vector platform was modified to allow 
for spectinomycin selection by replacing the bla cassette with the aadA cassette and 
allowed for expression and selection in C. trachomatis serovar L2. As predicted, the 
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CT228 mutant was deficient in CT228 and MYPT1 recruitment to the inclusion during 
infection. After determining, through RT-PCR, that no polar effects were observed whilst 
utilizing the CT228 mutant, complementation was performed by incorporation of CT228 
into the vector pBOMB4R, previously shown to successfully express host cell cytosolic 
chlamydial effector proteins (Bauler & Hackstadt, 2014). Upon complementation, 
MYPT1 recruitment was restored as demonstrated through immunofluorescent 
microscopy.  These findings demonstrate the second successful chlamydial adaptation of 
the TargeTronTM system to further characterize the role of CT228 in MYPT1 recruitment 
during C. trachomatis pathogenesis.   
Results 
Construction of the CT228 Mutant, ΔCT228 
 The chlamydial TargeTron adopted vector, pDFTT3(bla) was chosen for 
modification for use in C. trachomatis serovar L2 to genetically inactivate the protein, 
CT228.  Previously described, the vector pDFTT3 contains an Escherichia coli origin of 
replication, a cat marker for chloramphenicol selection and necessary intron genes: GII 
intron, ltrA and bla genes (Johnson and Fisher, 2013).  pDFTT3 was further modified by 
replacement of the bla gene with a spectinomycin cassette (aadA), allowing for mutant 
complementation using the shuttle vector, pBOMB4R. The resulting vector was then 
retargeted by PCR for antisense insertion into CT228 at 295 base pairs with an E-value of 
0.200 (Figure 2). Colonies carrying a disrupted CT228 gene were obtained and sequence 























Figure 2. Diagram of TargeTron intron insertion.  
A) A wild type locus map of CT228 reveals the predicted intron insertion site at bp 295 
with an E-value of 0.200. B) The diagram of the CT228:GII(aadA,) CT228 TargeTron, 
mutant reveals the incorporation of the GII(aadA) intron in an antisense manner into the 
predicted insertion site. Sanger sequencing established correct insertion, at the predicted 
site.   
CT228 Mutant Analysis  
 Polymerase Chain Reaction (PCR) was performed using CT228-specific primers 
flanking the GII(aadA) insertion site validated successful intron insertion (Figure 3, 
Reaction 2).  This result was visualized by the increase in mutant product size when 
compared to wild type.  To establish that the CT228 region was specifically disrupted, a 
PCR reaction was used with incA-gene specific primers.  IncA is utilized as a control to 
ensure that the chosen site of insertion was not affecting regions of the chromosome 
adjacent to CT228 (Figure 3, Reaction 1). To justify that the intron had not been lost 
during passage, PCR validation of the intron was observed in only the mutant (Figure 3, 
Reaction 3). Primers linking the GII(aadA) intron to CT228 demonstrated the anti-sense 
orientation of intron insertion relative to CT228 (Figure 3 Reactions 4 and 5). To further 
provide confidence in intron insertion, Sanger sequencing was utilized to validate intron 
insertion in an anti-sense manner into the predicted site at 295 bp. Furthermore, PCR was 
utilized to ensure that the chlamydial cryptic plasmid was not lost during passage or lost 
upon introduction of the TargeTron plasmid (Figure 3, Reaction 6). Established was the 
specific site-insertion of the GII(aadA) intron into CT228 in an anti-sense manner. 
However, with incA amplification observed upstream in the 3’ direction with respect to 
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CT228, it was possible downstream polar effects could be observed in the CT229-CT224 
operon, hindering expression of genes downstream.  
 
Figure 3. PCR Validation of CT228 Genetic Inactivation  
The TargeTron adapted vector, pDFTT(bla) was modified for use for the present study by 
replacing the bla gene with the aadA cassette to allow for selection using spectinomycin. 
The vector was retargeted for insertion into the predicted intron insertion site of the 
CT228 gene in serovar L2. PCR was utilized using a series of specific primers with 
template DNA derived from WT (wild-type; C. trachomatis L2), Mut (ΔCT228) or from 
pDFTT295 (intron) and reactions were assessed with gel electrophoresis. After PCR 
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validation, Sanger sequencing confirmed that the predicted site (295 bp) contained the 
intron in an anti-sense manner.  Figure provided courtesy of Dr. Derek Fisher. 
Expression Validation of the CT229-CT224 Operon 
 To establish that polar effects were not observed when using the mutant, reverse 
Transcriptase PCR (RT-PCR) was utilized with internal gene specific primers to each of 
the genes within the CT229-CT224 operon. RNA was extracted from HeLa 229 cell 
monolayers infected with C. trachomatis serovar L2 wild type EBs or mutant CT228 EBs 
at 24 hours post-infection.  RT-PCR was then used to check for gene expression for each 
gene within the operon (Figure 4).  CT228 is the second gene in the CT229-CT224 
operon and RT-PCR of CT229 showed amplification from both wild type and mutant 
cDNA. Thus, indicating that CT229, upstream from CT228 is independent of the 
mutation and that the cDNA synthesis was successful.  RT-PCR amplification of CT228 
showed that amplification was observed from both wild type and mutant RNA. 
Furthermore, comparison of the product sizes indicates that the intron was retained 
throughout the time course and was expressed.  RT-PCR for each gene downstream of 
CT228  (CT227, CT226, CT225 and CT224) from both wild type and mutant show 
amplification, thus providing that polar effects due to CT228 GII(aadA) insertion are not 
hindering expression of genes downstream of CT228. Furthermore, this ensured that 
future complementation of the mutant could be performed by the addition of the CT228 



















Figure 4. The CT229-CT224 operon of the CT228 mutant, ΔCT228, is free of polar 
effects 
To validate that the downstream genes of CT228 (CT227, CT226, CT225 and CT224) 
were not affected by the insertion of GII(aadA), RT-PCR was utilized.  RT-PCR was 
performed using internal gene-specific primers for each gene within the operon.  Panels 
display expression of all genes within the CT229-CT224 operon from both C. 






C. trachomatis CT228 Mutant Validation Protein Recruitment to the Inclusion 
Membrane 
 The inclusion membrane protein CT228 is localized to the inclusion membrane 
periphery during infection. To verify mutant loss of CT228 recruitment to the inclusion 
membrane, C. trachomatis L2 and CT228 mutant, ΔCT228, EBs were used to infect 
confluent HeLa 229 cell monolayers. At 36 hours post infection, when cells are infected 
and have observable large inclusions, cell monolayers were fixed and stained with anti-
CT228 and anti-total MYPT1 and corresponding secondary antibodies. 
Immunofluorescent microscopy was used to validate that in the mutant, ΔCT228 was 
deficient in CT228 production.  Furthermore, CT228 was not localized to the periphery 
of the inclusion in contrast to wild type localization of CT228 at the inclusion membrane 
(Figure 5).  
A component of myosin phosphatase, MYPT1, is known to interact with CT228 
during infection, affecting the dynamic of the host cell exit method of extrusion (Lutter et 
al., 2013).  Myosin Light Chain 2 (MLC2) is a known substrate of MYPT1. MYPT1 will 
enzymatically dephosphorylated MLC2, when active. MYPT1, when inactive and 
interacting with CT228, is prevented from the enzymatic function on the substrate MLC2. 
This leaves MLC2 in an active, phosphorylated state (Lutter et al., 2013).  Active MLC2 
is known to interact with binding partners, Myosin IIA and Myosin IIB to form a myosin 
motor complex, which in turn correlates with the host cell exit mechanism of extrusion.  
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 The loss of MYPT1 to the site of the inclusion periphery during infection with 
the CT228 mutant, ΔCT228 was observed in comparison to the presence of MYPT1 upon 
infection with C. trachomatis L2 (Figure 6). Thus, providing that in the mutant, MYPT1 
is not to the periphery during infection. When assessing recruitment of MLC2, Myosin 
IIA and Myosin IIB to the site of the inclusion during infection, phospho-specific 
antibodies were used as to detect the presence of phosphorylation states of the protein, 
which indicate activity of the overall protein.  As observed, MLC2, Myosin IIA and 
Myosin IIB are all recruited to discrete areas of kinase activity around the inclusion, 
called microdomains (Figures 6-9).  Adapted from previous investigations, staining with 
anti-Src (Src family kinases) is used as a marker for microdomains (Mital and Hackstadt, 
2011). Thus, providing evidence that these proteins are recruited to these areas in both 
wild type and mutant.  
 
Figure 5. Immunofluorescent microscopy verifies the loss of CT228 production in 
the CT228 mutant 
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HeLa 229 cell confluent monolayers were infected with C. trachomatis L2 wild type or 
CT228 mutant, ΔCT228. Infections were fixed with methanol and cells were stained with 
anti-LPS to visualize the inclusions within each cell and α-CT228 to observe the 
localization and production of CT228.  Observed above is the loss of CT228 production 
upon infection with CT228 mutant, ΔCT228. 
 
Figure 6. Immunofluorescent microscopy validates the loss MYPT1 recruitment in 
the CT228 mutant 
HeLa 229 cell confluent monolayers were infected with C. trachomatis L2, wild type, or 
CT228 mutant, ΔCT228, EBs. Infections were fixed with methanol and cells were stained 
with α-LPS to visualize the inclusions within each cell and α-MYPT1 (total; both 
phosphorylated and non-phosphorylated) to observe the localization to the inclusion 
membrane.  Observed above is the loss of MYPT1 recruitment to the inclusion membrane 










Figure 7. Immunofluorescent microscopy verifies the recruitment of MLC2 in the 
CT228 mutant 
HeLa 229 cell confluent monolayers were infected with C. trachomatis L2 Wild Type or 
CT228 mutant, ΔCT228, EBs. Following infections, monolayers were fixed with 
methanol and cells were stained with phospho-specific antibodies: anti-Src (pTyr419) and 
anti-MLC2 (pSer19) to visualize the recruitment of phosphorylated proteins to the 
inclusion membrane during infection. Observed above is the recruitment of MLC2 to 
microdomains of the inclusion membrane. This recruitment of MLC2 to the inclusion 
membrane during infection with mutant, ΔCT228, is similar to the recruitment observed 











Figure 8. Immunofluorescent microscopy reveals the recruitment of Myosin IIA in 
the mutant 
HeLa 229 cell confluent monolayers were infected with C. trachomatis L2 wild type, or 
CT228 mutant, ΔCT228, EBs. Infections were fixed with methanol and cells were stained 
with phospho-specific antibodies: anti-Src (pTyr419) and anti-Myosin IIA, to visualize 
the recruitment of phosphorylated proteins to the inclusion membrane during infection. 
Observed above is the recruitment of Myosin IIA to microdomains of the inclusion 
membrane. This recruitment of Myosin IIA to the inclusion membrane during infection 















Figure 9. Immunofluorescent microscopy establishes the presence of Myosin IIB in 
the mutant 
HeLa 229 cell confluent monolayers were infected with C. trachomatis L2 wild type, or 
CT228 mutant, ΔCT228, EBs. Infections were fixed with methanol and cells were stained 
with phospho-specific antibodies: anti-Src (pTyr419) and anti-Myosin IIB, to visualize 
the recruitment of phosphorylated proteins to the inclusion membrane during infection. 
Observed above is the recruitment of Myosin IIB to microdomains of the inclusion 
membrane. This recruitment of Myosin IIB to the inclusion membrane during infection 






Immunofluorescent Validation of the CT228 Mutant Complementation 
 A chlamydial adapted TargeTron mutation has yet to be complemented. As such, 
the goal was to complement the CT228 TargeTron mutant and verify the recruitment of 
proteins necessary for the host cell exit mechanism of extrusion, to the inclusion during 
infection.  The shuttle vector, pBOMB4R was utilized. The pBOMB4R vector has been 
used previously to investigate inclusion membrane proteins during infection (Weber et 
al., 2015).  Complementation of the CT228 mutant was possible as pBOMB4R contains a 
β-lactamase resistance cassette, allowing for selection by the addition of Penicillin G 
(Bauler & Hackstadt, 2014). The adaptation of the TargeTron plasmid, replacement the 
bla cassette with the aadA spectinomycin cassette, was instrumental for successful 
complementation of the mutant strain.  
CT228 was amplified from C. trachomatis serovar L2 434/Bu and was cloned into 
the BamHI and KpnI sites of pBOMB4R. Following sequence confirmation, the construct 
was transformed in CT228 mutant, ΔCT228, EBs. After several selective passages using 
Penicillin G, a clonal plaque was obtained and expanded (see Methods and Materials). 
The CT228 mutant complementation plasmid was used to infect confluent HeLa 229 cell 
monolayers, along with wild-type C. trachomatis serovar L2, and CT228 mutant, 
ΔCT228; allowing for a direct comparison of wild-type, mutant and complemented 
strains. Infected cell monolayers were fixed and stained with corresponding primary and 
secondary antibodies and subjected to immunofluorescent microscopy.  
Immunofluorescent microscopy analysis showed consistent results for C. 
trachomatis serovar L2.  Both CT228 and MYPT1 are shown to be present at the site of 
66	  
	  
the inclusion, surrounding the periphery of the inclusion during infection (Figures 9 and 
10, respectively). Also consistent with previous findings is the loss of CT228 and 
MYPT1 at the site of the inclusion during infection with ΔCT228 (Figures 10 and 11). 
However, upon infection by the mutant complement, ΔCT228C, CT228 is again present 
at the site of the inclusion in a similar manner to wild-type (Figure 10). However, the 
amount of protein recruitment appears to be at lower levels.  This could be partially in 
fact by the construct being under control of the rpoB promoter, allowing for low levels of 
constitutively expressed proteins.  Similarly, upon infection by the CT228 mutant 
complement, ΔCT228C, MYPT1 is also observed at the periphery of inclusion membrane 
during infection (Figure 11).  It is shown that complementation of the CT228 TargeTron 
mutant was successful, as MYPT1 recruitment to the inclusion during infection was 
restored. To further ensure that complementation of the mutant was indeed successful, 
Western blot analysis was utilized to confirm expression of CT228 in the complemented 























Figure 10. Immunofluorescent microscopy reveals restoration and localization of 
CT228 to the inclusion membrane when infecting with the complemented CT228 
mutant 
HeLa 229 cell confluent monolayers were infected with C. trachomatis L2 (wild type 
strain), ΔCT228 (CT228 mutant) or ΔCT228C (CT228 complemented mutant). Infections 
were fixed with methanol and cells were stained with anti-LPS to visualize the inclusions 
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within each HeLa 229 cell and α-CT228 to observe the localization and production of 
CT228.  Observed above is the loss of CT228 production upon infection with the mutant, 




Figure 11. Immunofluorescent microscopy verifies that CT228 complemented 
mutant restores MYPT1 recruitment upon infection 
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HeLa 229 cell confluent monolayers were infected with C. trachomatis L2 (wild type 
strain), ΔCT228 (mutant) or ΔCT228C (complemented mutant). Infections were fixed 
with methanol and cells were stained with anti-LPS to visualize the inclusions within 
each HeLa 229 cell and anti-MYPT1 (total; phosphorylated and non-phosphorylated) to 
observe the localization and production of CT228.  Observed above is the loss of MYPT1 
recruitment upon infection with the CT228 mutant, ΔCT228, and restoration of protein 
recruitment with the complemented mutant, ΔCT228C, similar to recruitment of wild 
type. 
Western Blot Analysis of Whole Cell Lysates Infected with C. trachomatis L2, 
ΔCT228 and ΔCT228C 
 To establish that the mutant was indeed deficient in CT228 production and that 
the CT228 mutant complementation had restored the CT228 protein deficit, HeLa 229 
cell confluent monolayers were infected with C. trachomatis L2 wild type, C. 
trachomatis serovar L2 CT228 mutant (ΔCT228) and C. trachomatis serovar L2 CT228 
mutant complement (ΔCT228C) at an MOI of approximately 1. At 36, 42 and 48 hours 
post infection, monolayers were lysed and collected with Laemmli buffer and subjected 
to SDS-PAGE gel electrophoresis. Samples were transferred to nitrocellulose membrane 
and resulting blots were developed using anti-MOMP and anti-CT228 primary antibodies 










Figure 12. Western Blot Analysis verifies production of CT228 in Wild Type, CT228 
Mutant and CT228 Mutant Complement  
Western blot analysis was used to assess whole cell lysates separated by SDS-PAGE and 
stained with α-CT228 at 36 hours post-infection. Consecutive bands at approximately 21 
kDa are apparent in lanes corresponding to wild type, L2 (left lane) CT228 mutant, 
ΔCT228 (middle lane) and the CT228 complemented mutant, ΔCT228C (right lane).  
Extrusion Assessment of C. trachomatis L2 Wild Type, CT228 Mutant and 
Complemented CT228 Mutant  
 To assess the differences of extrusion numbers between C. trachomatis L2 wild 
type, ΔCT228 mutant and ΔCT228C complemented mutant.  HeLa 229 cell confluent 
monolayers were infected at an MOI of approximately 1 for each strain. At 36, 42 and 48 
hours post-infection, supernatants were collected, spun by centrifugation, stained with 
1µL NucBlue® Live ReadyProbes® nucleic acid stain (Thermo Fisher Scientific) and 
enumerated for Chlamydia-filled host cell membrane encased extrusions, devoid of host 
cell nuclei. Statistical analysis was provided by Prism 7.0 using a one-way ANOVA 
multiple comparisons (Figure 13) However, it is plausible that contradictory results could 
be established if the use of a dam-dcm- methylation deficient plasmid was not used. This 
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could have decreased transformation efficiency producing such potential contradictory 
results. Furthermore, it is possible that differences in cell culturing procedures or 
extrusion collection and enumeration could also account for differences in contrasting 
phenotype (Key & Fisher, 2016). In	  addition,	  Hayes	  et	  al.	  report	  that	  the	  C.	  trachomats	  
serovar	  B/Jali-­‐20/OT	  Chlamydial	  major	  outer	  membrane	  protein	  (MOMP)	  sequence	  was	  found	  
to	  contain	  12	  point	  mutations	  within	  the	  genome	  in	  the	  region	  encoding	  for	  the	  major	  outer	  
membrane	  protein	  (MOMP)	  (Hayes	  et	  al.,	  1990).	  	  This	  yields	  the	  production	  of	  five	  amino	  acid	  
changes	  of	  MOMP,	  along	  with	  a	  known	  truncation	  event	  in	  the	  CT228	  gene	  (Seth-­‐Smith	  et	  al.,	  
2009;	  Zuck	  et	  al.,	  2016;	  Hayes	  et	  al.,	  1990).	  The	  C.	  trachomatis	  serovar	  L2	  CT228	  mutant,	  ΔCT228	  
possesses	  only	  the	  singe	  GII	  intron	  insertion	  mutation	  event	  in	  comparison	  to	  the	  C.	  trachomatis	  
serovar	  B	  strain,	  which	  naturally	  harbors	  additional	  mutation	  types.	  These	  differences	  of	  strain	  
type	  utilized	  in	  investigations,	  as	  well	  as	  mutations	  harbored	  within	  the	  strains	  can	  explain	  
differences	  observed	  in	  the	  results	  of	  extrusions,	  as	  it	  is	  quite	  possible	  the	  B/Jali	  strain	  is	  
mutated	  in	  other	  locations	  that	  could	  possibly	  have	  a	  role	  in	  the	  extrusion	  process.	  	  
 Collectively, extrusion numbers at every time point of collection, 36, 42 and 48 
hours post-infection, were found to be significant between groups L2 and mutant, 
ΔCT228, as well as CT228 mutant complement, ΔCT228C (*=P<0.01). However, 
statistical significance at every time point of collection, 36, 42 and 48 hours post-
infection, was not found to be between groups L2 and ΔCT228C (P>0.05). These 
findings suggest that extrusions were produced in significantly larger numbers by the 
CT228 mutant, ΔCT228, at each time point when compared to the wild-type or 
complemented strains.  Furthermore, there was an observable lack of statistical 
significance amongst wild-type and complemented strain produced extrusions. This 
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suggests that the complemented strain partially restored the extrusions phenotype, 
decreasing the numbers of overall produced extrusions, similar to the wild-type 
phenotype. While restoration to wild-type is not exact, this suggests a similar conclusion 
in comparison to immunofluorescent analysis: while restoration of the deficit is 
observable, it is indeed observable at low levels.  Again, this could be due to a couple 
factors.  First, the transformation efficiency could be lower than anticipated. Or, 
alternatively, expression under the control of the rpoB promoter in the pBOMB4R vector 
could be allowing for a lower level of expression, not high enough for full restoration of 
the deficit. In conclusion, complementation of the CT228 mutant was performed in trans 
by reintroduction of the CT228 as mediated by the shuttle vector, pBOMB4R. 
Complementation was observed to restore not only protein deficits, but additionally, 
recruitment to the inclusion membrane. Moreover, upon complementation of the mutant, 
the phenotypic extrusion host cell exit mechanism was restored.  Novel to the success of 
this investigation was this result, for the first time, the complementation of a chlamydial-
adapted use of the TargeTronTM system.  As such, it is evident that the TargeTron™ 
based gene inactivation system proves again to be a valid platform for which to continue 




Figure 13. Comparison of L2, ΔCT228 and ΔCT228C extrusion production at 36, 42 
and 48 hours post-infection. 
 At 36, 42 and 48 hours post-infection, supernatant was removed from Chlamydia-
infected HeLa 229 cell monolayers. Supernatant was stained to view live cell nucleic acid 
centrifuged to pellet extrusions. Samples were loaded onto glass slides with 
hemocytometer cover slips and 8 grids counted for each sample.  Results were analyzed 
(one way ANOVA) and graphed using Prism 7.0 (XY graph).  
Upon Western blot analysis, it was anticipated result that the mutant would yield a 
higher band, as there was previous evidence supporting such, as provided by RT-PCR.  
However, upon translation of the sequence of the mutant (provided by Dr. Derek Fisher 
in validation of the mutant), it was found that in Frame 3 of the results of translation there 
is a near 170 amino acid stretch which is translated immediately followed by two stop 
codons (Figure 14). Upon Western blot analysis, the expected size of the wild type 
protein is 196 amino acids as well as the complemented CT228 mutant.  However, in 
comparison, when taking the truncation event into consideration of the CT228 mutant, 
only a difference of 2 kDa would be observable on a Western Blot, a difference not 
observable by eye.  
Figure 14.  SIB ExPASy in silico Frame 3 translation results of the sequenced 
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ΔCT228 mutant shown in a 5’3’ manner. 
DNA sequencing of the ΔCT228 mutant were entered into the ExPASy translate tool 
provided by Swiss Institute of Bioinformatics. Observable is the start codon Met 
followed by a near 175 amino acid protein followed by two Stop codons.   
Discussion 
Historically, obligate intracellular pathogen, Chlamydia, was considered to be 
genetically intractable until 2001, when Wang et al. described the first transformation 
method.  From there, the genetic tools of which to investigate Chlamydia have advanced 
to chemical mutagenesis, chromosomal gene inactivation’s and even plasmid-based gene 
knock outs (Johnson & Fisher, 2013; Gerard et al., 2013; Kari et al., 2011; Nguyen & 
Valdivia, 2014).  Represented here, is the second adaptation of the chlamydial-based 
TargeTron™ system of which, genetic chromosomal inactivation of the chlamydial Inc, 
CT228, was accomplished.  
 In 2013, Johnson & Fisher were the first to report the successful utilization of the 
TargeTron™ system to genetically inactivate incA. The TargeTron™ system works by 
the incorporation of a non-coding region of DNA, the group II intron.  Insertion into a 
chosen site of a target gene is accomplished by the mode of an RNA protein complex, 
which is easy mutable with PCR. The utilization of the TargeTron™ system has also 
been used to investigate various other bacteria including Gram positive and other Gram 
negative, as well. However, to date, in the Chlamydial host, restoration of mutant deficit 
was not performed by complementation.  Importantly, this study is the first to 
complement a mutant TargeTron™ strain in trans to restore near wild-type phenotype.     
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 Adaptation, yet again, of the GII(bla) mutant, replacing the bla, beta-lactamase 
resistance cassette with the aadA, spectinomycin resistance gene, was essential to the 
success of this investigation.  This modification allowed for the selection of stable 
mutants possessing the mutation.  Furthermore, the modification allowed for 
complementation of the mutant by using the pBOMB4R shuttle vector, shown to work 
previously with inclusion membrane proteins (Bauler & Hackstadt, 2014). Adaptation of 
the TargeTron™ system was successful in the Chlamydial system once again, based on 
the non-essential function of CT228. Furthermore, validating that polar effects, when 
using the CT228 mutant, did not compromise operon expression was key in the 
successful complementation of the mutant. It was anticipated result that the mutant would 
yield a higher band by Western blot analysis as previous evidence was provided by RT-
PCR.  However, it was found that there is a truncation event, resulting in a near 170 
amino acid stretch, which is translated. Upon Western blot analysis, the expected size of 
the wild type protein is 196 amino acids as similarly observed in the complemented 
CT228 mutant.  However, in comparison, when taking the truncation event into 
consideration of the CT228 mutant, only a difference of 2 kDa would be observable on a 
Western Blot, a difference not observable by eye with use of this method. This 
discrepancy and difference could explain the Western Blot analysis results observed in 
this work. However, as a result, validity is provided to future use of this chromosomal 
inactivation system as it produces chlamydial proteins of which functionality is 
compromised are a result. The TargeTronTM system is thus warranted to serve again as a 
chlamydial investigational system to gain further future insight into protein function.   
Begin typing or pasting the rest of your chapter 4 text here. 
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IN VIVO COMPARISON OF CHLAMYDIAL STRAINS: C. TRACHOMATIS SEROVAR 
D/LC, C. TRACHOMATIS SEROVAR L2 AND C. MURIDARUM MOPN IN C3H/HEJ MICE 
 
Abstract 
Chlamydia trachomatis is the leading cause of bacterial sexually transmitted infections, 
preventable blindness, and is a risk factor for the development cervical cancer. Untreated, 
asymptomatic infection as well as frequent re-infection are common and drive pelvic 
inflammatory disease, ectopic pregnancy, and infertility.  In vivo models of infection 
continue to be instrumental in elucidating the pathogenesis of and immune response to 
this intracellular bacterium, however significant gaps in our understanding exist. The 
objective of this study was to produce a side-by-side comparative analysis in a 
cervicovaginal murine infection model utilizing the C. trachomatis serovars D and L2 
and the C. muridarum strain MoPn by characterizing the (i) time course of infection and 
Chlamydia shed, (ii) early, mid and late immune response to infection, and (iii) gross 
pathology following clearance of active infection. A key finding herein is the first 
identification of chlamydial extrusions shed from host cells in an in vivo model.
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Extrusions, a recently appreciated mode of host-cell exit and potential means of 
dissemination, had been previously observed solely in vitro. The results of this study 
demonstrate that chlamydial extrusions exist in vivo thus warrant further investigation to 
determine their role in chlamydial pathogenesis.   
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Introduction 
There are five recognized species of Chlamydia: C. trachomatis, C. pecorum, C. 
psittaci, C. pneumoniae and the most recently reclassified, C. muridarum, C. pecorum 
and C. psittacti are pathogens of mainly avian and lower animals, however human 
infections may occur.  C. pneumonaie is known for inflicting respiratory infections and 
can lead to the harmful development of arthrosclerosis and cardiovascular disease 
(Grayston, 2000). C. trachomatis is a pathogen of mucosal areas, causing ocular 
trachoma and urogenital infections. There are 15 serovariants: serovars A-C cause ocular 
trachoma, serovars D-K and L1-L3 are associated with urogenital sexually transmitted 
infections. Serovars D-K are less severe than serovars L1-L3 and may cause cervicitis 
and urethritis or may be asymptomatic. Pathologically distinct LGV infections caused by 
serovars L1-L3 are more invasive in nature and are characterized in infection through 
dissemination into distant lymph nodes near the site of infection by mediation of 
macrophages (Schachter, 1999; Burton and Mabey, 2009; Herweg & Rudel, 2016). 
Although an infection can be cleared with the use of antibiotics, ongoing complications 
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may arise after; such as pelvic inflammatory disease (PID), endometriosis, tubal scarring, 
ectopic pregnancy and even cervical cancer (Smith et al., 2001). Due to the similarities to 
C. trachomatis, C. muridarum, a mouse pneumonitis (MoPn) murine strain has used as a 
model to study C. trachomatis human infections (Ramsey et al., 2009).  
Chlamydiae are a group of obligate intracellular bacteria that possess a unique 
biphasic life cycle consisting of two alternating forms: infectious, non-replicative, 
extracellular elementary bodies (EBs) and non-infectious, metabolically active, 
replicative reticulate bodies (RBs) (Hackstadt, 1999). Upon binding of the EB to the host 
cell, the EB is endocytized and contained within a membrane bound vacuole, deemed an 
inclusion, and avoids lysosomal fusion (Moulder, 1991; Hackstadt et al. 1997). From 
within the protection of the inclusion, EBs quickly differentiate into metabolically active 
RBs, which replicate by mode of binary fission. Through a process of genomic DNA 
condensation and cross-linking of outer membranous proteins, the RBs then reorganize 
into infectious EBs. Upon the host cell swelling to fit the growing numbers of chlamydia, 
the Chlamydia will exit the cell by one of two mechanisms: lysis or extrusion (Todd & 
Caldwell, 1985; Hybiske & Stephens, 2007).  
Most recently, the mechanism of lytic escape was found to be dependent on a 
virulence-associated gene transcriptional regulator, Pgp4, encoded on a single plasmid 
possessed by many Chlamydia (Yang et al., 2015; Song et al. 2013). Alternatively, the 
extrusion mechanism of host cell exit, in which the inclusion exits the cell by budding out 
and pinching off, encased in host cell membrane, is regulated by interactions between 
host and chlamydial proteins at the site of the inclusion membrane. The chlamydial 
inclusion membrane protein, CT228, recruits a component of myosin phosphatase, 
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MYPT1, to the inclusion during infection to regulate the host cell exit mechanism of 
extrusion (Lutter et al., 2013).  However, current investigations have yet to identify 
existence of extrusions in vivo (Lutter et al., 2013; Hybiske & Stephens, 2007; Herweg & 
Rudel, 2016; Zuck et al. 2016; Chen et al., 2014).  Such findings could heighten the 
knowledge of chlamydial pathogenesis and provide validity into extrusion dissemination 
of infection to surrounding tissues.  
The use of the murine model to investigate chlamydial infections has been used 
widely due to close resemblance of acute genital tract infections in human females.  After 
infection, mice typically naturally resolve infections in approximately 4 weeks and 
develop subsequent immunity and after such, more than half of mice are typically 
resistant to reinfection (Morrison & Caldwell, 2002).   Differences in mouse immune 
response to infection occur between C. trachomatis strains and MoPn strains (Williams et 
al., 1981). MoPn has been described to be more virulent than C. trachomatis in mice, 
causing systemic infections and acute pathology in the genital tract (Nigg, 1942). Within 
days of primary infection, neutrophils and monocytes respond to the site of infection 
(Morrison & Morrison, 2000).  After neutrophil recruitment, T cell accumulation can be 
observed at the infection and maintain a critical role during and after infection clearance 
(Kelly & Rank, 1997; Darville et al., 1997; Ramsey & Rank, 1991; Morrison et al., 
1995).  Both CD4+ and CD8+ T cells can be observed during the course of infection, 
however CD4+ T cells predominate, and in small clusters can be observed in the genital 
tract mucosa until infection resolution.  
To date, much knowledge has been gained in infectivity, pathogenicity, fertility 
and potential vaccine candidates for MoPn and C. trachomatis infections in the murine 
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model (Hong et al., 2012, Pal et al., 1999; Schautteet et al., 2011). However, with 
numerous murine models used and due to the lack in consistency in strain usage, there is 
a wide gap in knowledge.  By characterizing and comparing strains of C. trachomatis 
serovar D/LC, serovar L2 and C. muridarum MoPn in vivo, a platform can be provided of 
which to form the basis of many investigations to come. Here, we demonstrate the first 
comparison of the ocular serovar D, the urogenital infecting serovar L2 of C. trachomatis 
and murine specific, MoPn of C. muridarum in vivo.  This comparison allows for insight 
into the time course of chlamydial infections and gross pathology following clearance of 
infection.  Furthermore, demonstrated is the complete first account of chlamydial 
extrusions in an in vivo murine model.  
 
Figure 15.  Time course of murine infection.  
  Six week old C3H-HeJ female mice were ordered from Jackson Laboratories and 
at 10 and 7 days prior to infection, mice were subcutaneously injected with Depo-provera 
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to synchronize estrous (Days -10 and -7, respectively).  Infection (Day 0) was performed 
by pipetting infectious Chlamydia serovars diluted in 1X SPG into the lower genital tract. 
Lower genital tracts were swabbed for infectious EBs at days 3, 7, 14, 21, 28, 35 and 59 
post-infection.  At days 10, 17, 24 and 31 post-infection, lower genital tracts were 
swabbed for the presence of extrusions.  At days 7, 35 and 65 post-infection, sera was 
obtained by whole blood collection.  Between days 28 and 35, lower vaginal tracts were 
flushed with bovine serum albumin to collect IgA. At day 65, remaining mice were 
euthanized and whole reproductive tracts were dissected, photographed for gross 
pathological comparisons, and sent for histopathology.   
Results 
Lower vaginal infection results in increased recoverable Infectious Forming Units of 
C. trachomatis serovar L2.  
Ten and 7 days prior to infection, mice were subcutaneously administered Depo-
provera (Pfizer, NY, NY) to synchronize estrous.  Mice were then separated into groups 
and infected in the lower genital tract with 1X106 EBs of a chlamydial strain: C. 
trachomatis serovar D/LC, C. trachomatis serovar L2 or C. muridarum MoPn. At days 3, 
7, 14, 21, 28, 35 and 59 post infection, mice were individually sedated and vaginally 
swabbed 8 rotations to the right and 8 rotations to the left for recoverable (Figure 15). 
Swabs were emerged in 1.5 mL sterile tubes with 600 µL of SPG buffer with two sterile 
glass beads. Samples were vortexed and serially diluted in HBSS and plated onto 
confluent HeLa 229 cell monolayers. Approximately 36-40 hours post-infection, infected 
cell monolayers were fixed with methanol and stained with appropriate primary and 
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secondary antibodies to visualize inclusions. Recoverable IFUs, means and standard 
deviations were calculated and graphed as a box and whisker plot (Microsoft Office 
Excel; PRISM 7) (Figure 16). 
At the beginning of the time course, the amounts of shedding of live organisms 
were within the same log scale, suggesting that all mice were infected equally. However, 
at day 7 post-infection, differences in live organism shedding between groups are evident. 
At day 14 post infection, group C. trachomatis serovar L2 mice exhibit a 3-log fold 
increase in recoverable live organisms compared to serovar C. trachomatis D/LC and C. 
muridarum MoPn. After day 21, all strain recoverable IFUs continue to decline. The 
presence of recoverable organisms within each group at day 35 post infection, suggested 
that a subsequent sampling needed to be performed at day 59 to ensure that the immune 
system had cleared the infection. It was evident that there is a near 2-log fold difference 
between the maximum produced extrusion levels of C. trachomatis serovar L2 compared 





Figure 16. Comparison of recoverable IFUs obtained from lower vaginal swabs in 
C3H/HeJ mice infected with Chlamydial serovars D, L2 and MoPn.  
Mice were Depo-Provera treated and vaginally infected with 1X 106 elementary 
bodies of corresponding serovar. Comparisons of recoverable IFUs were obtained by 
swabbing vaginal tracts and enumerating on HeLa 229 cell monolayers. Data is separated 
by chlamydial serovar and presented in logarithmic scale (log10) and separated by day. 
Group means are displayed as well as standard deviations by error bars.  
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Swabbing of vaginal tracts during Chlamydial infection reveals recoverable 
extrusions in vivo 
It is known that Chlamydiae may exit the host cell by one of two mechanisms: 
lysis or extrusion. Extrusions are defined to be chlamydial-filled, host membrane 
enveloped bodies devoid of host nuclei. The chlamydial extrusion process is defined in 
several steps involving, first, the protuberance of the inclusion out of the host cell, 
second, pinching of inclusion into distinct compartments and lastly, the separation of the 
pinched inclusion out of the cell to the periphery (Hybiske & Stephens, 2007). However, 
it was once assumed that extrusions were an artifact of tissue culture, with the majority of 
published extrusion images being derived in vitro or in situ (Neeper et al., 1990; Wyrick 
et al., 1993).  
A surprising finding within this study was establishing that extrusions were 
recoverable in vivo, showing that extrusions were not an artifact of tissue culture 
methods. Mice were individually swabbed at days 21 and 24 post infection. Swabs were 
placed into RPMI1640 media supplemented with 10% fetal bovine serum and subjected 
to staining with FM®4-64 plasma membrane dye and NucBlue® Live ReadyProbes® 
nucleic acid stain.  Samples were mixed gently and mounted onto glass slides for 
Confocal imaging (Olympus).  Images were obtained at 63iX magnification with 
immersion oil.  Images were obtained for differential interference contrast (DIC), FM®4-
64 (excitation 506 nm, emission 750nm) and NucBlue® Live ReadyProbes® (360 nm, 
emission 460 nm) (Figure 17).  DIC images show that extrusions recovered in vivo were 
consistent with extrusion derived from tissue culture in terms of shape.  While not all 
extrusions are perfectly spherical, evident through FM®4-64 staining, each extrusion is 
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in fact enveloped in host cell membrane (Zuck, et al. 2016).  Furthermore, as 
demonstrated by NucBlue® Live ReadyProbes® staining, each extrusion was found to be 
devoid of host cell nuclei.  As a conclusion, extrusions were recovered from live murine 
lower genital tracts from C. trachomatis serovar D/LC, C. trachomatis L2 and C. 
muridarum MoPn during the course of infection. 
 
 
Figure 17. Presence of extrusions in vivo after infection with Chlamydial serovars D, 
L2 and MoPn.  
Extrusions were found to be present from all Chlamydial serovars during 
infection in C3H/HeJ mice. Mice were Depo-provera treated and vaginally infected with 
1X106 elementary bodies of corresponding serovar or strain. Samples were obtained by 
swabbing the vaginal tract and collecting in RPMI 1640 medium supplemented with 10% 
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FBS.  Samples were stained with of NucBlue® Live ReadyProbes® Reagent and FM®4-
64 plasma membrane dye and mounted onto glass slides with glass coverslips.  Olympus 
Laser Scanning Confocal microscopy was used to obtain images above. Images were 
cropped, sized, aligned and adjusted for brightness using Adobe Photoshop.  
Observation of gross reproductive tracts reveals distinct differences in anatomical 
pathology following chlamydial infection 
To further assess upper reproductive tracts and to bridge a comparison between 
the recoverable live organisms to the pathological severity of infection, mice were 
subjected to gross pathological assessment.  It has been described that C3H/HeJ mice are 
susceptible to the development of hydrosalpinx following lower genital infection with C. 
muridarum (Chen et al., 2014; Lei et al., 2014).  The murine pathology very much 
mimics the tubal pathology observed in humans after a C. trachomatis infection (Lei et 
al., 2014).  
Upon imaging, SHAM mice, as a control, were found to possess healthy 
reproductive tracts: ovaries, uterine horns, and uterus. C. muridarum MoPn infected 
C3H/HeJ mice were found to have distinct observable pathology, bilateral hydrosalpix, 
consistent with previous findings within the same murine model (Chen et al., 2014). To 
establish a platform for further chlamydial investigations, it was necessary to perform a 
comparison of reproductive tracts with human C. trachomatis serovars typical of both 
ocular and genital infections. Comparison of anatomical sequelae after infection with C. 
trachomatis serovar D/LC and L2 revealed notable differences. Upon observation of 
reproductive tracts from D/LC mice was uterine horn inflammation, relatable to PID. In 
contrast, L2 mice had observable uterine horn occlusion and the presence of dark tissue 
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areas on the ovary. Comparison of mice reproductive tracts after infection demonstrates 
the differences in anatomical pathology following a lower genital tract infection.  Due to 
the differences observed in whole reproductive tracts, histopathological assessment was 
required to validate further establish a distinct pathology associated with infection of 
independent chlamydial strains.  
Figure 18. Anatomical assessment of murine reproductive tracts.  
At days 63 and 64 post infection, mice were euthanized and reproductive tracts 
were imaged and sent for histopathological assessment.  Individual images captured 
above demonstrate anatomical sequelea due to infection. (SHAM) Sample depicts a 
healthy reproductive tract. (D/LC) Top and bottom images depict observable right and 
left oviduct inflammation (white arrows). (L2) Top image depicts a black occlusion in the 
top portion of the left uterine horn (yellow arrow top). Bottom image depicts the presence 
89	  
	  
of dark tissue on ovary (bottom yellow arrow).  (MoPn) Top and bottom images depict 
observable hydrosalpinx near both right and left oviducts (green arrows top and bottom).     
Discussion 
The murine model has been used widely in past to investigate chlamydial 
bacteriology and pathology of the host after infection. However, with numerous murine 
strains available for use, and numerous pathogenic chlamydial strains, a platform 
establishing the clear differences in pathology, recoverable live organisms and 
immunological response was lacking.  This investigation proves to be sufficient for 
establishing such a platform for which to base future investigations.  The data from the 
present study taken together with previous findings suggest that the pathology of host 
reproductive tissues and recoverable shed live organisms do not necessarily correlate to 
the severity of infection.  Evident from the assessment of live recoverable organisms is 
that C. trachomatis serovar L2, yielded nearly 3-log fold more recoverable infectious 
forming progeny compared to C. trachomatis serovar D/LC and C. muridarum MoPn 
(Figure 15). Unique of this investigation, was the use of C. trachomatis serovar D/LC for 
comparisons. The usage of this strain was relevant in that in human hosts, the infection 
may present for long periods of time until subsequent treatment.  In past literature, 
Sturdevant et al. identified that when using C3H/HeJ mice were used as a model for C. 
trachomatis serovar D infection, there are two clearance phenotypes observed: early and 
late (Sturdevant et al., 2010). For this study, the serovar D late clearing phenotype was 
used to infect mice, to produce an overall, more virulent infection.  Consistent with 
findings is that serovar D/LC infection produces a long lasting infection, clearing after 
day 35 post-infection.    Furthermore, all mice were observed to clear infections by day 
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59 post-infection. This result was consistent with findings from research performed in 
both in vivo and in situ approaches (Lyons et al. 2005; Ito et al., 1990).  
When comparing the results of recoverable IFU studies to the anatomical sequelae 
pathology, it was evident that despite a lower level of shed live organisms, C. muridarum 
MoPn infections had a long lasting effect on reproductive tracts, causing the development 
of hydrosalpinx in all mice, consistent with previous findings (Chen et al., 2014). 
However, in comparison to C. trachomatis serovar D/LC infected mice, a difference was 
noted in terms of gross observation of reproductive tracts.  Serovar D/LC infected mice 
had less distinct differences in reproductive tracts, but rather the consistent presence of 
inflammation within each individual mouse, suggestive of the development of PID. 
Unique of C. trachomatis serovar L2 infected mice was the presence of a dark colored, 
uterine horn occlusion as well as dark growths on the ovary (Figure 18). As a conclusion 
of anatomical sequelae after the infection had resolved, notable differences, unique to 
serovar of infection were noted.  
Human infection of C. trachomatis is linked to the development of serious 
sequelae amongst women, such as pelvic inflammatory disease (PID). (Brunham et al., 
1988). PID is associated with inflammation of the uterus, fallopian tubes and ovaries in 
the human and is thought to be a development following a viral or bacterial infection 
(Paavonen et al., 2008). Gynecological consequences of PID in the human often result in 
ectopic pregnancy, infertility, and damage to the fallopian tubes (Chow et al., 1990; Ness 
et al., 2008; Robertson et al., 1987; Stamm 2008; Westrom et al., 1992).  These 
consequences are a result from damage to the cilia lining of the fallopian tube or due to 
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occlusions or adhesion formation (Safrin et al., 1993; Stacey et al., 1992; Buchan et al., 
1993).  
Upon infection of the host cell by Chlamydia, there resides a process of which 
irreparable damage is produced in host tissue.  Specifically, it is the non-immune host 
epithelial cells, which produce the most inflammatory response, driving the inflammatory 
response in which the result is the release of tissue damaging molecules (Rasmussen, et 
al. 1997). The production of matrix metalloproteases (MMPs) by the host cell and the 
release of cytokines and chemokines from adjacent macrophages, it is observable that 
proteolysis and remodeling of infected and adjacent tissue occurs.  Continued release of 
chemokines from Chlamydia-infected cells drives adaptive T cells and B cells to be 
recruited, following the initial recruitment of neutrophils and monocytes (Morrison & 
Morrison, 2000; Rank & Barron, 1983).  Specifically, the Interleukin 1 (IL-1) release has 
been shown to have a novel role in the pathogenesis of reproductive tract pathology 
following and infection (Hvid, et al. 2007). Furthermore, the production of tumor 
necrosis factor (TNF) leads to increased expression of adhesion molecules, which then 
leads to activation of the innate, then, adaptive immune system to target the Chlamydial 
infection (Ault et al., 1996; Kelly et al., 2001). It is well characterized that after these 
immune responses, damage to the genital tract is observed in the form of scarring. 
However, the scarring is observed to be in the area of infection, despite the resolve of 
inflammatory processes (Darville & Hiltke, 2010).  As taken as a result collectively from 
gross pathological assessment of murine reproductive tracts following a long term 
infection, it was presumable that upper genital tract pathology was present in the form of 
inflammation.  This agrees with past findings of reproductive pathology  in C3H mice 
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following a Chlamydial infection , as it is more often observed to be  more severe than 
other mouse strains (Darville et al. 1997; de la Maza et al., 1994).   
Due to the lack of a comparative assessment of C. trachomatis infections within 
the same murine strain, both ocular and genital strains, D/LC and L2, respectively were 
introduced into the C3H/HeJ murine model to allow for direct comparison. This allowed 
for the evaluation of the development of PID within the murine model when infecting 
with C. trachomatis serovars D/LC and L2. A goal of this study was to assess gross 
pathological differences amongst mice groups following infection (gross pathology 
images provided in Figure 17).   
An aim of this study was to identify extrusions derived from a live in vivo murine 
model. Consistent with the definition of an extrusion, being chlamydial-filled, host 
membrane enveloped bodies devoid of host nuclei, images were obtained from mice 
infected with each chlamydial strain demonstrating the existence of extrusions retrieved 
from live C3H/HeJ mice. The chlamydial extrusion process is separated in a series of 
steps: (i) protuberance of the inclusion out of the host cell, (ii) pinching of inclusion into 
distinct compartments (iii) separation of the pinched inclusion out of the cell to the 
periphery (Hybiske & Stephens, 2007). With this finding, we demonstrate that previously 
accepted knowledge of extrusions being derived by in vitro and in situ methods solely is 
no longer the case, thus leading to new questions of chlamydial pathogenesis (Neeper et 
al., 1990; Wyrick et al., 1993).  As a conclusion on the existence of extrusions retrieved 
from live C3H/HeJ mice infected with C. trachomatis and C. muridarum, it was found 
that extrusions are in fact being shed from the vaginal tract during infection with all three 
strains, which was provided by Confocal microscopy analysis. Following infection with 
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each strain of Chlamydia, extrusions were found to be encased in host cell plasma 
membrane, as provided by staining with FM4-64 that is specific for plasma membrane. 
Furthermore, NucBlue Live DNA stain provided that these extrusions were devoid of 
host cell nuclei, currently fitting the description of extrusions as being host cell 
membrane encased, Chlamydia-filled spherical sacs, which are devoid of host cell nuclei. 
This was essential in differentiating that it was not a possibility that the inclusion was 
expelled from host cells lysed by the swabbing process. However, enumeration was not a 
possible result of this experiment.  There lies a possibility that the enumeration of 
extrusions was not a possibility due to the physiological nature of the vaginal tract from 
which samples were taken.  There lie a few possibilities of explaining this enumeration 
difficulty. First, it is possible that the vaginal acidity could be responsible for decreased 
extrusion events being retrieved from the vaginal tract.  The pH of the vagina is known to 
be moderately acidic, fluctuating along with hormonal changes throughout the estrous 
cycle (Kelly, 1990).  Also affected by hormonal cycles in the vagina is mucosal secretion 
(Sharif  & Olufowobi, 2006). It is possible that extrusions were retained within the 
cervical mucosal secretions during the infection timeline.  Observed in this study is that 
the fluidity of cervical secretions varied amongst strains used for infection.  There lies a 
real possibility that the cervical mucous retained the extrusions. In conclusion, due to 
possibility that the careful experimental design of retrieving the extrusions without 
agitation or centrifugation, extrusions could either be lost during or prior to sampling due 
to pH acidity in the vagina or, quite possibly extrusions could be retained in mucosal 
secretions in the sample following processing and might not located in the media of 
which was used for wet mounting methods.	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Considering that the host cell exit method of extrusion is indeed occurring in vivo, 
future research should be focused on further characterizing chlamydial-host interactions 
involving chlamydial protein, CT228 as well as identifying the advantage to which 
Chlamydiae obtain by utilizing this mechanism of host cell exit.  It was been suggested 
by in vitro methodological approaches that Chlamydiae utilize the host cell exit 
mechanism of extrusion to subsequently promote engulfment by macrophages (Zuck et 
al., 2016; Herweg & Rudel, 2016). Aside from the novel identification of recoverable 
extrusions derived after a chlamydial infection in vivo, in this present study, we have 
demonstrated the comparable levels of recoverable IFUs derived from C3H/HeJ vaginal 
tracts infected with chlamydial strains C. trachomatis serovar D/LC, C. trachomatis 
serovar L2 and C. muridarum MoPn.  Furthermore, gross anatomical reproductive tract 
assessment and histopathological analysis at days 64 and 65 post-infection revealed 
distinct characteristics specific to chlamydial strain infection. Thus, we demonstrate that 
a platform for future investigations is established; C3H/HeJ mice are ideal for chlamydial 
infections of the murine model. This work provides a basis for further investigations into 
chlamydial-host pathogenesis.  
 
SUMMARY OF CHLAMYDIAL-HOST INTERACTIONS 
Chlamydia trachomatis is the bacterial causative agent of the most commonly 
reported urogenital sexually transmitted infection (STI) worldwide (Newman et al., 
2015). While main public health concerns are focused on C. trachomatis urogenital 
infection, C. trachomatis is also known to infect other mucosal sites such as the eye, 
causing infectious blindness or more commonly known as, trachoma. Chlamydial STIs 
are often presented asymptomatically, however females have a risk for the development 
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of tubal infertility and scarring and PID as a sequelae after infection and male 
counterparts exhibit the risk for development of epididymitis and urethritis (Brunham et 
al., 1984; Mishori et al., 2012). Recently, it has been suggested that antimicrobial 
therapies continued for up to 6 months following infection hold the possibility treating 
some of these sequelae (Carter et al., 2010). However, the best plan of prevention against 
the transmission of chlamydial infections is by practicing abstinence.  
Chlamydiae are obligate intracellular biphasic pathogens which reside and 
replicate within a parasitophoros vacuole, deemed an inclusion (Moulder, 1991).  Upon 
endocytosis into the host cell, the infectious elementary body (EB) will congregate to 
form a single inclusion where the EBs will rapidly differentiate into metabolically active, 
non-infectious reticulate bodies (RBs) (Hybiske & Stephens, 2007). From within the 
inclusion, Chlamydiae must highjack and redirect cellular traffic for growth and 
development. The bacterium is capable of doing such through the T3SSin which 
Chlamydia synthesized proteins are secreted to interact with host cell proteins at either 
the site of the inclusion membrane, or alternatively, will be secreted into the host cell 
cytosol (Dean, 2011; Kleba & Stephens, 2008).  
As a result of growth and replication, the large numbers of Chlamydia will cause 
the host cell to swell, making escape necessary for a productive infection to result.  
Chlamydia may exit the cell by one of two mechanisms: lysis or extrusion.  The lytic host 
cell escape mechanism is reliant upon a systematic procedure of permeabilization events 
regulated by the Chlamydial transcriptional regulator, Pgp4 (Hybiske & Stephens, 2007; 
Yang et al., 2015). Whereas, the chlamydial host cell exit mechanism of extrusion is 
regulated by a highly dynamic, enzymatic pathway involving interaction of chlamydial 
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inclusion membrane protein CT228 with a host cell protein and component of myosin 
phosphatase, MYPT1 (Lutter et al., 2013).   
The chlamydial host cell exit mechanism of extrusion was once thought to be an 
artifact of tissue culture, as no in vivo investigations resulted in the recovery of viable 
extrusions. During investigations of the in vivo comparison of chlamydial infections, it 
was a question of if extrusions were being produced. Surprisingly, extrusions were 
detected from all strains used for the study, roughly about 3 weeks post-infection. 
Extrusions were identified as being host cell membrane encased, Chlamydia-filled 
inclusions, devoid of host cell nuclei, separate from the host cell.  As a conclusion, for the 
first time to date, it is observed that extrusions are recoverable from a live animal model 
following urogenital Chlamydia infection.  This adds significant knowledge to the 
Chlamydial field, as investigations can now focus more on host-pathogen interactions 
involving host cell exit and pathogenesis.  
In the near future, for the first time in vivo, a Chlamydial TargeTron™ CT228 
mutant, ΔCT228 will be used for live murine infection studies. It will be interesting to 
observe if extrusion levels are heightened when sampling from the infected live animal 
model as predicted, based on in vitro preliminary date presented in this study.  
Furthermore, consistent with past findings, when using the murine infection model, there 
is a distinct pathological sequelae: tubal occlusion, PID, inflammation and hydrosalpinx 
development. Identification of pathological sequelae following infection with the first 
Chlamydial mutant should yield strong insight into differences between wild-type and 
mutant, as this has not be yet performed. The merging of the two projects at hand, into 
one complete in vivo analysis of the CT228 mutant will yield great insight into 
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Chlamydial pathogenesis as there are current limitations of in vitro and in situ based 
approaches.  
Benefits of the TargeTron™ system adaptation include higher insertion 
efficiencies when compared to homologous recombination methods, minimal host system 
requirements and a relatively short amount of time to produce a mutant strain (Perutka et 
al., 2003; Chen et al., 2005). However, when utilizing the TargeTron™ Chlamydial 
adapted system, it was a possibility that polar effects would result as the incorporation of 
the Group II intron could affect expression of downstream genes, as CT228 is second in 
line of the CT229-CT224 operon.  Due to the fact that promoter studies have not been 
performed within the operon, there was a chance that polar effects resided after genetic 
mutation.  By performing RT-PCR we ruled out that polar effects were observed from the 
operon when using the CT228 TargeTron™ mutant.  
Newer genetic tools are already being developed within the Chlamydial field as a 
result of the original adaptation, such as by gene deletion by fluorescence reported allelic 
exchange mutagenesis (FRAEM), which would allow for gene deletion rather than 
mutation.  This adaptation allows for further investigational studies without 
compromising bacterial growth, essential when utilizing intracellular bacteria (Mueller et 
al., 2016). The Chlamydial field has a long road ahead in terms of genetic methodologies; 
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Figure A1. Kyte and Doolittle hydrophobicity plot of the Inc CT228.  
Hydrophobicity analysis of translated amino acids provided of CT228 sequence provide that two 





      
Figure A2: C. trachomatis and C. muridarum CT228 homology. 
CT228 of C. trachomatis and of C. muridarum was found to be more than 50% conserved. 
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